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The Role of the Human Tau 3’-Untranslated Region in Regulating Tau Expression 
Abstract 
The microtubule-associated protein tau forms pathological neuronal filaments in 
Alzheimer’s disease (AD) and other neurodegenerative disorders, known collectively as 
tauopathies.  Previous studies in transgenic mouse models of AD suggest that reducing tau 
expression may be safe and beneficial for the prevention or treatment of AD and possibly other 
tauopathies.  As a first step toward identifying novel therapeutic strategies to reduce tau levels, 
the studies presented in this dissertation aim to investigate the role of the human tau 3’-
untranslated region (3’-UTR) in regulating tau expression.  Tau expresses two 3’-UTR isoforms, 
long and short, as a result of alternative polyadenylation.  The exact sequence of these two 3’-
UTR isoforms was determined by rapid amplification of cDNA 3’-ends (3’-RACE), and the two 
3’-UTR isoforms were cloned into a luciferase reporter vector.  Using these reporter constructs, 
the expression of these isoforms was found to be differentially controlled in human 
neuroblastoma cell lines M17D and SH-SY5Y by luciferase assays and quantitative PCR 
(qPCR).  Through an unbiased screen of tau 3’-UTR deletions and fragments using luciferase 
reporter constructs, several regions in the long tau 3’-UTR isoform that contain regulatory cis-
elements were identified.  Additionally, several microRNAs were computationally identified as 
candidates that might bind the long tau 3’-UTR and thereby differentially control the expression 
of long versus short tau 3’-UTR isoforms.  Screening these candidate microRNAs via luciferase 
reporter assay identified miR-34a, which was subsequently shown to repress the expression of 
endogenous tau protein and mRNA in M17D cells using Western blot and qPCR, respectively.  
Conversely, inhibition of endogenously expressed miR-34 family members leads to increased 
	  iv 
endogenous tau expression.  Taken together, these studies suggest that the expression of the two 
tau 3’-UTR isoforms is differentially regulated and that this differential regulation is due to the 
presence of regulatory cis-elements found only in the long tau 3’-UTR isoform, including a 
binding site for miR-34 family members.   Improved understanding of the regulation of tau 
expression by its 3’-UTR may ultimately lead to the development of novel therapeutic strategies 
for the treatment of Alzheimer’s disease and other tauopathies. 
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Introduction 
The tau protein was initially reported in 1975 as an essential factor for the in vitro 
assembly of tubulin into microtubules (Weingarten, 1975).  This protein was given the name of 
the Greek letter tau (τ) because it causes tubule assembly (Weingarten, 1975).  Subsequently, the 
tau protein was found to form abnormal aggregates in several different neurodegenerative 
disease, known collectively as tauopathies (Lee et al., 2001).  Because of its involvement in 
microtubule assembly and in neurodegenerative diseases, studying the biology of tau can provide 
insights into normal cellular physiology and disease pathophysiology. 
The Normal Biology of Tau 
Tau Gene Structure 
 Orthologs of the tau gene have been identified in species ranging from humans (Homo 
sapiens) to zebrafish (Danio rerio) (Chen et al., 2009); thus, tau is broadly conserved in bony 
vertebrates (Euteleostomi).  The human tau gene, MAPT (microtubule-associated protein tau), is 
located on chromosome 17q21 (Neve et al., 1986) in an area of complete linkage disequilibrium 
(Baker et al., 1999).  As a result, two haplotypes MAPT exist:  H1 and H2, with H1 being the 
more common variant.  These two haplotypes are defined by a series of single nucleotide 
polymorphisms (SNPs), as well as a 238 basepair (bp) deletion in intron 9 of the H2 haplotype 
(Baker et al., 1999).  The existence of these two non-recombining haplotypes is explained by a 
900 kilobase (kb) inversion polymorphism for chromosome 17q21.31, which contains the MAPT 
gene, as well as several other genes (Figure 1.1) (Stefansson et al., 2005). 
 The promoter of region of the MAPT gene is GC-rich; lacks TATA and CAAT boxes; 
and contains binding sites for Sp1, AP-2, and additional, as yet unidentified, transcription factors 
(Andreadis et al., 1996; Heicklen-Klein and Ginzburg, 2000; Sadot et al., 1996).  The core  
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Figure 1.1.  H1 and H2 Haplotypes.  There is a 900 kb inversion of the H2 haplotype relative 
to the H1 haplotype.  The MAPT gene is in this region, along with CRHR1, IMP5, and NSF 1-
13.  Adapted from Caffrey and Wade-Martins (Caffrey and Wade-Martins, 2007)66. 
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promoter, which is active in both neuronal and non-neuronal cell types, is located within 
nucleotides -302 to +4 relative to the +1 transcription start site (TSS) (Maloney and Lahiri, 
2012).  Distal regulatory sequences both upstream and downstream of the TSS conferred neuron-
specific regulation of expression on the tau promoter (Maloney and Lahiri, 2012). 
 The MAPT gene consists of 16 exons, half of which are alternatively spliced (Figure 1.2), 
which is discussed in more detail below (Andreadis, 2005).  The 5’-untranslated region (5’-UTR) 
is encoded by exon -1 (Andreadis et al., 1992), and it contains an internal ribosomal entry site 
(IRES), allowing for 5’ cap-independent translation of tau mRNA (Veo and Krushel, 2009; 
2012).  The coding region is encoded by exons 1 to 13.  In humans and rats (Rattus norvegicus), 
intron 13 is retained between exons 13 and 14; thus the 3’-untranslated region (3’-UTR) is 
comprised of exon 13, intron 13, and exon 14.  In mice (Mus musculus) and cows (Bos taurus), 
some tau transcripts have been found to have intron 13 spliced out (Himmler, 1989; Poorkaj et 
al., 2001).  The tau 3’-UTR will be discusses in more detail below. 
 It should be noted that Saitohin (STH), a small intronless gene, is encoded entirely within 
intron 9 of the human MAPT gene.  The Saitohin protein is 128 amino acids in length and does 
not share clear homology with other proteins (Conrad et al., 2002).  While the function of 
Saitohin remains an open question, it has been reported to bind tau, peroxiredoxin 6, and c-Abl 
(Gao et al., 2005; Wang et al., 2011). 
Alternative Splicing of Tau 
 The extensive alternative splicing of tau mRNA allows for the generation of a diversity of 
tau transcripts.  The alternative splicing of tau is spatially and temporally regulated, with (a) 
characteristic isoform(s) being expressed in a given tissue at a given developmental stage.  In 
some cases, the alternative splicing also appears to be species-specific (Andreadis, 2005). 
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Figure 1.2.  General Structure of the MAPT Gene.  Exons are numbered.  Black exons are 
constitutively expressed.  Gray exons can undergo alternative splicing.  Adapted from 
Andreadis (Andreadis, 2005). 
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The alternative splicing of exons 2 and 3 are related and fall into the category of 
“augmented combinatorial” alternative splicing (Andreadis, 2005).  Exon 3 is only spliced into 
the transcript if it contains exon 2.  Exon 2 may be spliced out (referred to as 0N), exon 2 may be 
spliced in without exon 3 (referred to as 1N), or exon 2 and exon 3 may be spliced in (referred to 
as 2N) (Andreadis, 2005; Andreadis et al., 1992).  Both exon 2 and 3 are comprised of 87 
nucleotides (nt) in humans (Andreadis et al., 1992). 
 Exon 4A is the largest of the tau exons, with a length of 753 in humans (Andreadis et al., 
1992).  It is included in tau mRNA in the peripheral nervous system (PNS), retina, and spinal 
cord, but it is spliced out of tau transcripts in other regions of the central nervous system (CNS) 
(Couchie et al., 1992; Georgieff et al., 1993).  Exon 4A is thought to increase the spacing of 
microtubules in axons of neurons in which it is expressed (Georgieff et al., 1993) 
 Exon 6, which is 198 nt long in humans (Andreadis et al., 1992), is included in a minority 
of tau transcripts; however, it has been detected in fetal brain, skeletal muscle, and spinal cord 
(Wei and Andreadis, 1998).  Inclusion of exon 6 has been found to inhibit neurite elongation in 
differentiated SH-SY5Y human neuroblastoma cells (Luo et al., 2004a).  In addition to the 
canonical 3’-splice site of exon 6, two cryptic 3’-splice sites exist within exon.  Utilization of 
either of these cryptic 3’-splice sites would result in a frame shift and introduction of premature 
stop codon in either exon 6 or exon 7, depending on which cryptic 3’-splice site were used (Wei 
and Andreadis, 1998).  One of these truncated tau proteins has been identified in vivo (Luo et al., 
2004b), and the truncated protein, which lacks the microtubule binding domain, has been found 
to inhibit polymerization of full-length tau protein in vitro (LaPointe et al., 2009). 
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 Exon 8 has not been studied extensively.  It is included in some transcripts from cow 
(Chen et al., 1994; Himmler, 1989) and rhesus macaques (Macaca mulatta) (Nelson et al., 1996).  
However, it has not been found in human tau (Chen et al., 1994). 
 Exon 10, which is 93 nt long in humans, is a cassette exon that encodes one of four 
imperfect repeats of the microtubule binding domain of tau; thus, exclusion of exon 10 from the 
tau transcript results in 3-repeat (3R) tau, whereas inclusion of exon 10 results in 4-repeat (4R) 
tau (Andreadis et al., 1992; Goedert et al., 1989a; 1989b).  Dysregulation of exon 10 has been 
implicated in disease, which will be discussed in more detail below. 
 As noted above, in some species intron 13 is retained between exons 13 and 14, while in 
others it may be spliced out.  In rodents, the 3’-splice site for exon 14 has the sequence 
acagGAA, whereas the corresponding sequence in humans is acaGAA.  Thus, unlike rodents, 
humans lack the cagG consensus sequence of a 3’-splice site at the site where exon 14 should 
begin, which may explain why splicing out of intron 13 has not been observed in humans 
(Poorkaj et al., 2001).  As a result, the generic mammalian sequences of exon 13, intron 13, and 
exon 14 all comprise the terminal exon of the human tau gene, which includes the 3’-end of the 
coding region, the stop codon, and the 3’-UTR.  Additionally, multiple 5’-splice sites for exon 13 
have been identified in mice and cows (Himmler, 1989; Lee et al., 1988). 
 Despite the diversity of possible tau transcripts resulting from alternative splicing, six 
isoforms are predominantly found in the human brain.  These isoforms are produced by the 
alternative splicing of exons 2, 3, and 10, with the possible combinations being 0N3R, 1N3R, 
2N3R, 0N4R, 1N4R, and 2N4R (Figure 1.3).  The 0N3R isoform predominates in fetal human 
brain, while all six isoforms are found in adult human brain (Andreadis, 2005; Andreadis et al., 
1992). 
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Figure 1.3.  The 6 Major Tau mRNA Splice Isoforms in the Adult CNS. 
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General Tau Expression Patterns 
 While the expression pattern for some tau splice isoforms is mentioned in the previous 
section, the general expression patterns for tau will be discussed here.  Tau is predominantly 
expressed in the nervous system; however, tau expression has been detected in several non-
neural tissues (Drubin et al., 1986; Gu et al., 1996).  In the CNS, two tau transcripts, 
approximately 2 and 6 kb in length, have been observed (Goedert et al., 1988; Neve et al., 1986; 
Wang et al., 1993).  These transcripts are formed by alternative polyadenylation (APA) of tau 
mRNA, which produces two 3’-UTR isoforms.  The 2 kb transcript corresponds to the short tau 
3’-UTR isoform, and the 6 kb transcript corresponds to the long tau 3’-UTR isoform (Poorkaj et 
al., 2001).  In the CNS, the 6 kb transcript tends to be the predominant isoform (Goedert et al., 
1988; Wang et al., 1993).  In neurons, the 6 kb tau transcript is localized to the axon and soma 
(Litman et al., 1993; Poorkaj et al., 2001), and tau protein is enriched in axons (Binder et al., 
1985; Peng et al., 1986).  Although tau is predominantly an axonal protein, it has been found in 
the nucleus, and it has been hypothesized that there is a link between the 2 kb transcript and 
nuclear tau (Wang et al., 1993), but no definitive evidence of this has been reported.  It should be 
noted that an approximately 8 kb tau transcript is expressed in the PNS, and it corresponds to 
transcripts containing exon 4a (Couchie et al., 1992; Goedert et al., 1992). 
The Tau 3’-UTR Isoforms 
 Although it has been known for decades that tau mRNA undergoes APA to produce two 
3’-UTR isoform (Goedert et al., 1988; Poorkaj et al., 2001; Wang et al., 1993), no studies 
specifically addressing the functional consequences of the APA of tau have been reported.  
However, some regulatory functions of the long tau 3’-UTR isoform in rodents have been 
	  	  10 
reported.  Before the functions of rodent tau 3’-UTR are discussed, a more general overview of 
3’-UTR functions is provided.   
In general, 3’-UTRs have a variety of functions in regulating gene expression, such as 3’-
end processing, translational regulation, stability, and subcellular localization of the transcript 
(Figure 1.4) (Barrett et al., 2012).  These regulatory roles are mediated by the interaction of cis-
elements in the 3’-UTR and trans-factors, which include proteins and microRNAs (miRNAs), in 
the cell (Chen et al., 2006).  An additional level of regulation results from APA, which can occur 
in transcripts that contain two or more polyadenylation signals (PASs).  Transcripts that undergo 
APA express alternative 3’-UTR isoforms, which can be differentially regulated by either the 
inclusion or exclusion of regulatory cis-elements (Shi, 2012). 
 The rodent tau 3’-UTR has been shown to play a role in the stability, translational 
efficiency, and subcellular localization of tau mRNA.  Aronov and colleagues identified a U-rich 
region of the rat tau 3’-UTR that increases the stability of tau mRNA (Aronov et al., 1999), 
which was later shown to bind the embryonic lethal abnormal vision (ELAV)-like protein HuD 
(Aranda-Abreu et al., 1999).  The insulin-like growth factor mRNA binding protein 1 (IMP-1) 
and Ras-GTPase-activating protein SH3-domain-binding protein 1 (G3BP-1) were subsequently 
shown to bind mouse tau mRNA and HuD (Atlas et al., 2004).  HuD, IMP-1, and G3BP-1 
repress the translation of a luciferase reporter containing the mouse tau 3’-UTR (Atlas et al., 
2007).  While HuD binds the rat tau 3’-UTR at a U-rich sequence (Aranda-Abreu et al., 1999), 
IMP-1 binds the mouse tau 3’-UTR at a site distinct from HuD in a sequence-independent 
manner that may instead depend on a structural feature in the 3’-UTR (Atlas et al., 2007).  This 
is possible, as a sequence-independent, stem-loop-containing regulatory cis-element, known as  
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Figure 1.4.  Central Dogma in Eukaryotes.  Aspects regulated by 3’-UTRs are highlighted. 
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the stem-loop destabilizing element (SLDE), has been found in the 3’-UTR of interleukin (IL)-2, 
IL-6, and granulocyte colony-stimulating factor (G-CSF) (Brown et al., 1996).   
 The rodent tau 3’-UTR is also involved in directing the subcellular localization of tau 
mRNA.  By transfecting primary neurons derived from rat embryos with a reporter plasmid 
containing different regions of the rat tau 3’-UTR downstream of a reporter gene, Behar and 
coworkers identified a region of the rat tau 3’-UTR involved in targeting the transcript to the 
axon (Behar et al., 1995).  This region is the same one that stabilizes tau mRNA and binds HuD 
(Aranda-Abreu et al., 1999; Aronov et al., 1999).  It was later shown that HuD and kinesin 
family member 3A (KIF3A) colocalize in axons of neuronally differentiated P19 rat embryonic 
carcinoma cell lines with the mRNA of a construct containing green fluorescent protein (GFP) 
fused to the tau coding region followed by a fragment of the rat tau 3’-UTR containing the 
axonal localization signal. This study also demonstrated that knocking down KIF3A resulted in 
neurite retraction and prevented the axonal targeting of tau mRNA (Aronov et al., 2002).  Since 
KIF3A is a microtubule motor protein involved in anterograde axonal transport (Hirokawa, 
2000), these data are consistent with the observation that tau mRNA is associated with 
microtubules in rat primary neuronal cell cultures (Litman et al., 1994). 
 While the studies discussed above provide insights into the function of the rodent tau 3’-
UTR, it is difficult to extrapolate these findings to the human tau 3’-UTR.  The U-rich region in 
the rodent tau 3’-UTR that binds HuD is not well-conserved in humans (Poorkaj et al., 2001).  
Since the IMP-1 binding site may be a sequence-independent structural feature of the rodent 3’-
UTR (Atlas et al., 2007), this would prevent identification of an IMP-1 binding site in humans 
based on a comparative primary sequence analysis of human and rodent 3’-UTRs.  Therefore, 
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further studies specifically on the human tau 3’-UTR are need to understand its role in regulating 
tau expression and to identify the cis-elements and trans-factors involved in this process. 
Structure of the Tau Protein 
 In its native state, soluble tau protein has little, if any, secondary structural features, as 
determined by circular dichroism spectroscopy (Bergen et al., 2005; Cleveland et al., 1977; 
Schweers et al., 1994).  The N-terminal region of the tau protein, known as the projection 
domain, mediates interactions between tau and components of the plasma membrane (Brandt et 
al., 1995) and between tau and Fyn, a Src family tyrosine kinase(Ittner et al., 2010; Lee et al., 
1998; 2004).  The proline-rich middle of the tau protein, known as the hinge region, has been 
implicated in influencing microtubule binding (Goode et al., 1997) and regulating neurite 
elongation (Luo et al., 2004a).  The C-terminal region contains the microtubule binding repeats 
(Himmler et al., 1989; Lee et al., 1989). 
Functions of the Tau Protein 
 Tau was identified as a factor that promoted the assembly of microtubules in vitro 
(Weingarten, 1975).  It was later shown to increase microtubule assembly and stability in cells 
(Drubin and Kirschner, 1986).  Since axonal transport occurs along microtubules and since tau 
bound to microtubules has been shown to block progression of kinesin and dynein along 
microtubules, tau has been implicated in regulating axonal transport (Dixit et al., 2008).  The 
phosphorylation state of tau regulates its affinity for microtubules, with increased 
phosphorylation resulting in a decreased affinity (Biernat et al., 1993; Lindwall and Cole, 1984).  
Alternative splicing also regulates the affinity of tau for microtubules.  Tau containing exon 10 
(4R tau) has approximately 3-fold higher affinity for microtubules than tau lacking exon 10 (3R 
tau) (Goode, 2000). 
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 Tau also plays a role in the function of Fyn.  Fyn is a non-receptor tyrosine kinase of the 
Src family that is implicated in signaling processes in a variety of cell types, particularly in the 
nervous and immune systems (Saito et al., 2010).  One notable function of Fyn signaling in the 
nervous system is the upregulation of N-methyl-D-aspartate (NMDA) receptors (NMDARs) 
(Trepanier et al., 2012).  The N-terminus of tau binds Fyn via a PXXP motif in the tau projection 
domain (Lee et al., 1998), and Fyn phosphorylates tyrosine 18 in the N-terminal region of tau 
(Lee et al., 2004).  Although the tau protein is enriched in axons (Binder et al., 1985; Peng et al., 
1986), it has recently been found to play a role in dendrites, in which it targets Fyn to the 
postsynapse (Ittner et al., 2010).  Tau and Fyn also interact in oligodendrocytes, and interrupting 
their interaction inhibits the outgrowth of oligodendrocyte processes (Klein et al., 2002). 
 Recently, it was reported that tau possesses intrinsic acetyltransferase activity and that it 
can catalyze autoacetylation.  The catalytic cysteines are apparently located within the 
microtubule domains (Friedmann et al., 2013).  Acetylation of tau has been found to inhibit its 
ability to promote the assembly and stability of microtubules (Cohen et al., 2011).  As this is a 
new area of investigation, it is not yet clear if tau acetylates other proteins (Friedmann et al., 
2013). 
Tau in Disease 
Alzheimer’s Disease 
 Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive 
cognitive decline (Cummings, 2004).  It is the most common form of dementia (Jones, 2003), 
with an estimated 5.2 million Americans suffering from the disease in 2013 (Alzheimer's 
Association, 2013).  Amnestic memory impairment is the most common presenting symptom of 
AD, but other common symptoms include language deficits (e.g. word-finding difficulty), 
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visuospatial deficits (e.g. impaired object or face recognition), and executive function deficits 
(e.g. impaired reasoning or judgment) (McKhann et al., 2011).  A possible or probable diagnosis 
of AD can be made based on the clinical presentation of symptoms; however, a definitive 
diagnosis of AD requires confirmatory histopathological findings in addition to the clinical 
diagnosis (Cummings, 2004). 
 Several neuropathological abnormalities can be found in the brain tissue from AD 
patients.  Two types of abnormal protein aggregates are seen in AD brains:  extracellular 
aggregates known as senile plaques and intracellular aggregates known as neurofibrillary tangles 
(NFTs) (Hyman et al., 2012).  Characteristic patterns for the deposition of these aggregates over 
the course of the disease have been described (Braak and Braak, 1991).  While there is some 
inter-individual variation, the progression of senile plaque deposition is classified according to 
three stages.  In stage A, senile plaques are present at low density in the isocortex.  In stage B, 
plaques are present at moderate density in the isocortex and at a low density in the hippocampus.  
In stage C, the isocortex has a high density of senile plaques, with a similar plaque burden in the 
hippocampus as in stage B.  Also in stage C, senile plaques begin to be found in subcortical 
structures (Braak and Braak, 1991).  A more consistent pattern of progression over the course of 
the disease is seen for NFTs, allowing for a delineation of six stages.  However, these stages can 
be categorized into three groups, each containing two stages that share similar features.  For 
simplicity, the stages will be presented in the three groups here.  In the transentorhinal stages 
(stages I and II) the transentorhinal region, which is transition zone between the entorhinal cortex 
and the temporal isocortex, is preferentially affected with NFTs, with mild involvement of the 
hippocampus.  In the limbic stages (stages III and IV), the involvement of the transentorhinal 
region and entorhinal cortex have progressed, a mild-to-moderate NFT burden is found in the 
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hippocampus, and the isocortex is mildly affected.  The isocortical stages (stages V and VI) 
show marked involvement of the entorhinal cortex and hippocampus, isocortical NFTs are a 
prominent feature, and NFTs are found in subcortical structures (Braak and Braak, 1991).  
Interestingly, the burden of NFTs but not senile plaques is associated with AD severity (Bierer et 
al., 1995).  In addition to these two protein aggregates, other pathological changes can been seen 
in the gross and histopathological examination of AD brains, including atrophy, neuron loss, 
synapse loss, and gliosis (Hyman et al., 2012). 
 Through the purification and sequencing of senile plaques, the major component of these 
protein aggregates was found to be a 4 kDa peptide that became known as the amyloid β (Aβ) 
peptide (Masters et al., 1985).  It was later recognized that Aβ was a fragment of a larger 
transmembrane protein, which was called the amyloid precursor protein (APP), encoded by the 
APP gene on human chromosome 21 (Goldgaber et al., 1987; Kang et al., 1987; Robakis et al., 
1987; Tanzi et al., 1987).  Of note, individuals with trisomy 21, also known as Down’s 
syndrome, are at an increased risk of developing AD (Visootsak and Sherman, 2007).  
Eventually, causative mutations in the APP gene were discovered in cases of familial AD (Goate 
et al., 1991; Hendriks et al., 1992; Mullan et al., 1992).  Additional familial AD mutations were 
identified in members of the presenilin family, PSEN1 and PSEN2 (Levy-Lahad et al., 1995a; 
1995b; Rogaev et al., 1995; Sherrington et al., 1995).  Either PSEN1 or PSEN2 can serve as the 
catalytic subunit of the γ-secretase complex, which is involved in the proteolytic processing of 
APP to Aβ (Kimberly et al., 2000; Wolfe et al., 1999). 
 As with senile plaques, efforts were made to identify the components of NFTs, and these 
studies revealed tau to be the major protein in these aggregates (Delacourte and Defossez, 1986; 
Grundke-Iqbal et al., 1986; Kosik et al., 1986; Nukina and Ihara, 1986; Wood et al., 1986).  
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Another notable finding from examining NFTs, is that the tau contained within them is 
hyperphosphorylated (Morishima-Kawashima et al., 1995).  Unlike the case with the Aβ, no 
mutations related to tau have been found in familial AD. 
 The fact that causative mutations in APP, PSEN1, and PSEN2 were found in cases of 
familial AD and that individuals with trisomy 21, in which three copies of the APP gene are 
present, are at a higher risk for developing AD suggests a key role for Aβ in the development of 
AD.  This led to the development of the amyloid cascade hypothesis, which states that the 
deposition of Aβ is the initial insult in the pathogenesis of AD.  In this hypothesis, other events 
involved in AD, such as NFT formation and neuronal loss, occur downstream of Aβ deposition 
in the cascade (Hardy and Higgins, 1992).  While the amyloid cascade hypothesis suggests that 
Aβ and tau participate in the same pathogenic pathway in AD, the precise molecular mechanisms 
that link the dysregulation of Aβ and tau have yet to be elucidated.  However, some studies have 
shown that Aβ can induce hyperphosphorylation and/or proteolytic cleavage of tau, so these 
processes may be involved (Wolfe, 2012).  Identifying the relationship between Aβ and tau in 
AD pathogenesis remains one of the key open questions in the field of neurodegeneration.  In 
addition to the amyloid cascade hypothesis, other hypotheses for the pathogenesis of AD have 
been proposed, for example an axonal transport impairment hypothesis (Saper et al., 1987) or the 
tau axis hypothesis (Ittner and Götz, 2010).  However, the amyloid cascade hypothesis is 
currently the most widely accepted hypothesis for AD pathogenesis. 
 Although alterations in tau are not considered to be an initial event in the pathogenesis of 
AD, mounting evidence suggests it is a key player in the pathophysiology of AD.  Cultured 
hippocampal neurons from homozygous tau knockout mice failed to develop the Aβ-induced 
cytotoxicity (Rapoport et al., 2002) and axonal transport defects (Vossel et al., 2010) seen in 
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wild-type hippocampal neurons.  Similarly, knock out of tau in APP/PSEN1 transgenic mouse 
models of AD results in improved learning and/or memory (Ittner et al., 2010; Leroy et al., 2012; 
Roberson et al., 2007), increased survival (Ittner et al., 2010; Leroy et al., 2012; Roberson et al., 
2007), and reduced excitotoxicity (Ittner et al., 2010; Roberson et al., 2007) compared with 
littermates with wild-type tau.  Ittner and colleagues provided mechanistic insights as to the 
reason for these findings by showing that loss of tau prevented tau from targeting Fyn to the 
postsynape, which decreased phosphorylation of NMDARs and reduced excitotoxicity (Ittner et 
al., 2010).  Several tau knockout mouse strains have been generated, and they have a surprisingly 
normal phenotype (Ke et al., 2012).  However, in one strain, aged tau knockout mice did develop 
muscle weakness, hyperactivity in a new environment, and impaired contextual fear conditioning 
(Ikegami et al., 2000).  Since a reduction in tau levels can prevent Aβ-induced toxicity and since 
most tau knockout mouse strains have a normal phenotype, a reduction of tau expression may be 
an effective therapeutic strategy for treating AD. 
Frontotemporal Lobar Degeneration 
 Frontotemporal lobar degeneration (FTLD) is a term that describes the heterogeneous 
clinical and neuropathological entities that possess the common phenotype of neurodegeneration 
in the frontal and temporal cortices of the brain.  As a result of the brain regions affected, 
common symptoms include behavioral changes, impairment of executive function, and language 
deficits (Seltman and Matthews, 2012).  FTLD can be subdivided into three main clinical 
syndromes based on the prominent early feature in that syndrome.  The behavioral variant 
frontotemporal dementia (bvFTD) is characterized by changes in behavior and loss of executive 
function due to frontal lobe atrophy.  Semantic dementia (SD) is characterized by deficits in 
semantic knowledge due to anterior temporal lobe atrophy (left-sided atrophy is more 
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pronounced than on the right).  Progressive non-fluent aphasia (PNFA) is associated with left 
peri-sylvian atrophy, which results in deficits in expressive or motor speech (Neary et al., 1998; 
Seltman and Matthews, 2012).  In addition to these “pure” cases of FTLD, there is significant 
clinical, neuropathological, and genetic overlap with other neurodegenerative diseases:  
amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), and cortiobasal 
degeneration (CBD) (Seltman and Matthews, 2012). 
 Neuropathological examination of the brain of a patient with FTLD typically shows 
neuronal loss in the affected area, which may be accompanied by white matter myelin loss and/or 
astrocytic gliosis.  Abnormal intracellular protein aggregates are also a hallmark of FTLD, but 
the specific nature of the aggregate depends on the neuropathological subtype of FTLD (Cairns 
et al., 2007). 
 One of the intraneuronal pathological aggregates that occurs in FTLD is called a Pick 
body, which was first described by Alois Alzheimer and is named after Arnold Pick, the first to 
describe clinical cases of frontal and temporal lobe atrophy that are now considered in the FTLD 
spectrum.  Pick’s disease was a term that was formerly used to describe cases that are now 
included in the bvFTD category, and Pick bodies were seen in brains of patients with Pick’s 
disease (Seltman and Matthews, 2012).  Pick bodies were eventually shown to contain tau 
protein (Murayama et al., 1990), particularly 3R tau that lacks exon 10 (Delacourte et al., 1998).  
Thus, one of the main neuropathological subtypes of FTLD is classified as tau-positive FTLD 
(FTLD-tau) (Mackenzie et al., 2009). 
 In a familial subtype of FTLD known as frontotemporal dementia with parkinsonism 
linked to chromosome 17 (FTDP-17) (Foster et al., 1997), causative mutations in the MAPT gene 
were identified (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998).  Over three 
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dozen tau mutations have described, and they tend to cluster in the C-terminal microtubule 
binding region.  Some of these mutations affect exon 10 splicing, some decrease the affinity of 
tau for microtubules, and others make tau more aggregation prone (Wolfe, 2008).  The presence 
of tau mutations in cases of FTDP-17, together with the evidence discussed above for its role in 
AD, strongly suggests tau can play a critical, and sometimes even causative, role in 
neurodegeneration. 
 Besides tau, other protein aggregates are seen in FTLD.  In some cases of FTLD and 
ALS, the aggregates are composed of TAR DNA-binding protein of 43 kDa (TDP-43) (Arai et 
al., 2006; Neumann et al., 2006).  These cases are classified as TDP-43-positive FTDL (FTLD-
TDP) (Mackenzie et al., 2009).  TDP-43 is an RNA-binding protein that is implicated in a 
variety of RNA-related processes, including splicing, mRNA stability, and mRNA trafficking.  A 
variety of mutations in TDP-43 have been described in cases of FTLD and ALS (Lee et al., 
2011).  In other cases of FTLD and ALS, aggregates are composed of the fused in sarcoma 
(FUS) protein (Kwiatkowski et al., 2009; Neumann et al., 2009).  These cases are classified as 
FUS-positive FTLD (FTLD-FUS) (Seltman and Matthews, 2012).  Like TDP-43, FUS is an 
RNA-binding protein involved in several aspects of RNA metabolism (Baloh, 2012).  Together, 
FTLD-tau, -TDP, and -FUS, make up a majority of the FTLD cases.  However, there are other 
cases of FTLD that are classified as ubiquitin proteasome system-positive (FTLD-UPS), type IV 
intermediate filament-positive (FTLD-IF), or no inclusion (FTLD-ni) (Mackenzie et al., 2009; 
Seltman and Matthews, 2012). 
Progressive Supranuclear Palsy 
 Progressive supranucelar palsy (PSP) is a neurodegenerative tauopathy that can present 
as a heterogeneous set of clinical syndromes.  The classic symptoms of PSP present in what is 
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known as Richardson’s syndrome and include supranuclear gaze palsy, parkinsonism, and 
postural instability.  PSP is named for the characteristic supranuclear gaze palsy finding, which 
prevents downward gaze.  Unlike in Parkinson’s disease, the parkinsonian symptoms in PSP 
respond minimally with levodopa therapy (Boeve, 2012).  The neuropathological findings in PSP 
include tau-containing NFTs, neuronal loss, and gliosis primarily in the basal ganglia, 
diencephalon, and brain stem (Dickson et al., 2010).  In PSP, an increase in the tau 4R/3R ratio 
has been noted (Takanashi et al., 2002).  While no causative genetic mutations have been linked 
to PSP, the H1 haplotype of the MAPT gene confers an increased risk of developing PSP 
(Pittman, 2005). 
Corticobasal Degeneration 
 Like PSP, corticobasal degeneration (CBD) is a neurodegenerative tauopathy that can 
have a variety of clinical presentations.  It is also referred to as corticobasal syndrome (CBS) to 
reflect that fact.  In addition to this heterogeneity within the disease, there is significant overlap 
in symptoms with other neurodegenerative diseases, such as FTLD and PSP.  Common 
symptoms of CBD include parkinsonism with a mild-to-moderate response to levodopa, apraxia, 
alien limb phenomenon, language impairment, and cognitive impairment (Armstrong et al., 
2013).  Tau-positive inclusions are seen in neurons, oligodendricytes, and astrocytes in the 
frontal and parietal cortices, as well in as the basal ganglia (Dickson et al., 2002).  Like PSP, an 
increased tau 4R/3R ratio is seen in CBD (Takanashi et al., 2002), and the H1 haplotype of the 
MAPT gene is associated with an increased risk of developing CBD (Pittman, 2005). 
Other Tauopathies 
 There are a number of additional tauopathies, and it is impossible to adequately discuss 
all of them here.  Instead, a few general principles will be mentioned.  In some tauopathies, tau 
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aggregates are the predominant neuropathological feature, while in others, additional types of 
aggregates may be found.  While tau’s mechanistic role in the pathogenesis of some tauopathies, 
particularly AD and FTLD-tau, is becoming clearer, it is unclear if and how tau contributes to the 
development of other tauopathies.  What is clear, however, is that tau aggregation is a 
commonality among a number of neurodegenerative disorders (Lee et al., 2001). 
Summary 
 The microtubule associated protein tau has important physiological functions, including 
promoting microtubule assembly and stability (Drubin and Kirschner, 1986; Weingarten, 1975) 
and dendritic targeting of Fyn to the postsynapse (Ittner et al., 2010).  Additionally, tau is 
implicated in a number of neurodegenerative diseases, which are known as tauopathies (Lee et 
al., 2001).  Tau plays a critical role in the pathogenesis of AD (Ittner et al., 2010; Leroy et al., 
2012; Roberson et al., 2007) and FTDP-17 (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini 
et al., 1998).  As a result, many aspects of tau biology have been studied extensively.  One aspect 
of tau biology that has been relatively understudied, especially in humans, is the role of its 3’-
UTR in regulating tau expression.  A more complete understanding of the function of the human 
tau 3’-UTR will provide insights into the basic biology of tau.  Additionally, it may aid in the 
identification of novel therapeutic strategies to reduce tau expression in AD and other 
tauopathies.  Therefore, the studies presented in this dissertation aim to investigate the role of the 
human tau 3’-UTR in regulating tau expression. 
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Chapter 2 
Alternative Polyadenylation of Tau mRNA Regulates Tau Expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental contributions to this chapter:  John Dickson performed the 3’-RACE, cloning, 
transfections, dual luciferase assays, and qPCR.  Rachel Moda, an undergraduate student at 
Harvard College, Cambridge, MA, assisted with performing site-directed mutagenesis under the 
supervision of John Dickson. 
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Introduction 
 The presence of multiple functional PASs at the 3’end of a gene allows for APA to occur, 
which produces alternative 3’-UTR isoforms.  Since different 3’-UTR isoforms may include or 
exclude certain regulatory cis-elements, APA is a mechanism of regulating gene expression (Shi, 
2012).  The tau gene, MAPT, contains two PASs in tandem, separated by approximately 4,000 nt.  
Thus, tau can undergo APA to produce a short 3’-UTR isoform that is approximately 2 kb in 
length and a long 3’-UTR isoform that is approximately 6 kb in length (Poorkaj et al., 2001).  
Despite the recognition that APA of tau occurs, there are no reports of the functional significance 
of the APA of tau.  The goals of the experiments presented in this chapter are to explore the role 
APA plays in regulating tau expression. 
Methods 
3’-RACE 
Rapid Amplification of cDNA 3’-Ends (3’-RACE) was performed on human frontal 
cortex total RNA (Agilent Technologies) with the FirstChoice RLM-RACE Kit (Life 
Technologies) using primers targeting the short and long human tau 3’-UTR isoforms (Table 
2.1).  An overview of the 3’-RACE protocol is provided in Figure 2.1.  The FirstChoice RLM-
RACE Kit contains the reverse transcriptase, 3’-RACE adaptor, adaptor primer, heat-stable DNA 
polymerase, and buffers used in the 3’-RACE protocol.  The 3’-RACE products were subjected 
to agarose gel electrophoresis and gel extraction as described below.  The purified 3’-RACE 
products were sequenced and aligned with human MAPT using ClustalW (Larkin et al., 2007). 
Cell Culture 
 All cells were cultured at 37 ºC in a 5% CO2 atmosphere. Primary human neonatal 
dermal fibroblasts (ATCC) were cultured in Fibroblast Basal Medium (a proprietary formulation  
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Figure 2.1.  General Overview of the 3’-RACE Protocol.  GSP stands for gene specific 
primer. 
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Table 2.1.  Primers for 3’-RACE. 
Purpose Location Orientation Sequence (5’ to 3’) 
3’-RACE 
Reverse 
Transcription 
Adaptor 
 
Poly(A) 
Tail 
Reverse GCGAGCACAGAATTAATACGACTCACTATAGG-
(T)12-VN 
 
3’-RACE Outer 
Primer 
 
3’-RACE 
Adaptor 
Reverse GCTGATGGCGATGAATGAACACTG 
Short Tau 3’-
UTR Primer 
 
Tau 3’-UTR 
112-134 
Forward TCGGTTAATTGGTTAATCACTTA 
Long Tau 3’-
UTR Primer 
Tau 3’-UTR 
3531-3550 
Forward CCACTGACAGGCTTTCCCAG 
 
of amino acids, vitamins, other organic compounds, trace minerals and inorganic salts designed 
to support fibroblast growth) supplemented with Fibroblast Growth Kit—Low Serum (ATCC).  
The Fibroblast Growth Kit—Low Serum adds the following components to the Fibroblast Basal 
Medium to achieve the final concentrations given: L-glutamine (7.5 mM), rh FGF beta (5 
ng/mL), rh Insulin (5 µg/mL), hydrocortisone (1 µg/mL), ascorbic acid (50 µg/mL), fetal bovine 
serum (FBS, 2%).  M17D human neuroblastoma cells (kind gift of Dennis Selkoe) and Human 
Embryonic Kidney (HEK) 293 cells (ATCC) were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM, Life Technologies) supplemented with 10% heat-inactivated FBS (Sigma-
Aldrich) and L-glutamine (Life Technologies).  SH-SY5Y human neuroblastoma cells were 
cultured in 1:1 Eagle’s Minimal Essential Medium (EMEM): Ham’s F-12 Medium (Sigma-
Aldrich) supplemented with 10% FBS (ATCC).  SH-SY5Y cells were differentiated using a 
modified version of a previously published protocol (Encinas et al., 2000).  Briefly, SH-SY5Y 
cells were plated on fibronectin-coated plates (BD-Biosciences) and treated with 10 µM retinoic 
acid (Sigma-Aldrich) in 1:1 EMEM:Ham’s F-12 Medium supplemented with 10% FBS for 7 
days.  The SH-SY5Y cells were then treated with 50 ng/mL brain-derived neurotrophic factor 
(BDNF, Life Technologies) in 1:1 EMEM:Ham’s F-12 Medium (without FBS) for 3 days. 
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Isolation of genomic DNA 
 Genomic DNA was isolated from primary human neonatal dermal fibroblasts using the 
DNeasy Tissue Kit (Qiagen) according to the manufacturer’s instructions.  Briefly, cells are 
lysed with Proteinase K, and the lysate is added to a spin column containing a silica-based 
membrane that adsorbs DNA at high concentrations of chaotropic salts.  The DNA can be 
conveniently washed to remove impurities while adsorbed to the membrane.  The purified DNA 
is then eluted from the column in a low-salt buffer or water. 
Polymerase Chain Reaction (PCR) 
 The wild-type human tau 3’-UTR sequence was amplified from genomic DNA derived 
from primary human neonatal dermal fibroblasts by PCR using KAPA HiFi HotStart ReadyMix 
(Kapa Biosystems) according to the manufacturer’s instructions, with an annealing temperature 
of 65 ºC.  KAPA HiFi HotStart ReadyMix is a high-fidelity heat-stable DNA polymerase that 
comes in a convenient format with the polymerase, buffer, and deoxyribonucleotide 
triphosphates (dNTPs) premixed into a master mix.  Template DNA, forward and reverse 
primers, and water to bring the components to the final concentration are added to this master 
mix, which is then subjected to 25 cycles of PCR with denaturation, annealing, and extension 
steps.  The resulting cloned construct from this DNA (described below) served as a template for 
PCR of the short tau 3’-UTR isoform.  The primers used for PCR are listed in Table 2.2. 
Restriction Digest of the pmirGLO Vector 
 The pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega) is a 
luciferase reporter vector that contains the firefly luciferase coding region, the expression of 
which is driven by the human phosphoglycerate kinase promoter.  Located 3’ of the stop codon 
of the firefly luciferase coding region is a multiple cloning site containing several unique  
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Table 2.2.  Primers for PCR of Full-Length Wildtype and Short Tau 3’-UTR Sequences. 
Construct Tau 3’-UTR 
Location 
Orientation Sequence (5’ to 3’) 
Tau3UTR_WT 
 
1-15 Forward GCTCGCTAGCCTCGAGTCAGGCCCCTGGGGC 
Tau3UTR_WT 
 
4451-4465 Reverse ATGCCTGCAGGTCGACTGGTGCCGGTCTTGC 
Tau3UTR_short 
 
1-15 Forward GCTCGCTAGCCTCGAGTCAGGCCCCTGGGGC 
Tau3UTR_short 223-256 Reverse ATGCCTGCAGGTCGACTGAATGTTTTTTTTTAAA
TATTTTATTACTAGCC 
 
restriction sites that can be used for cloning inserts into that region.  Sequences cloned into the 
multiple cloning site are included in the 3’-UTR of the reporter gene.  Thus, this luciferase 
reporter is useful in studying the function of 3’-UTRs from genes of interest.  Also included in 
the pmirGLO vector is a completely different luciferase gene, that of the Renilla luciferase, the 
expression of which is driven by the SV40 early enhancer/promoter.  The Renilla luciferase 
expression is not influenced by the sequence cloned into the multiple cloning site; thus, it serves 
as a normalization control for transfection efficiency.  The vector also contains an ampicillin 
resistance gene for selection in bacteria. 
The pmirGLO vector was subjected to a double digest by the restriction endonucleases 
XhoI and SalI (New England Biolabs) in 1X Buffer 3 (New England Biolabs) and 1X bovine 
serum albumin at 37ºC overnight.  
Agarose Gel Electrophoresis 
 DNA was subjected to agarose gel electrophoresis using 0.8% (for large DNA fragments) 
to 2% (for small DNA fragments) agarose gel in 1X Tris-Acetate-EDTA (TAE) buffer (Life 
Technologies) at a constant voltage of 110V.  DNA bands were stained with ethidium bromide 
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(Sigma-Aldrich) or SYBR Safe DNA Gel Stain (Life Technologies) and visualized under 
ultraviolet (UV) illumination. 
Gel Extraction of DNA 
 DNA bands were cut out of the agarose gel and gel extracted using the NucleoSpin PCR 
Clean-Up and Gel Extraction kit (Macherey-Nagel) according to the manufacturer’s instructions.  
This DNA purification kit works by a similar principle as the DNeasy Tissue Kit. 
Cloning 
 The desired sequences were inserted into the pmirGLO vector between the XhoI and SalI 
restriction sites using the In-Fusion HD EcoDry Cloning Kit (Clontech) according to the 
manufacturer’s instructions.  The In-Fusion HD EcoDry Cloning Kit includes an enzyme that 
possesses 3’-to-5’ exonuclease activity that generates approximately 15 bp of a ssDNA overhang 
at the 5’-end of linear dsDNA.  If different strands of dsDNA have complementary ends, they 
can anneal at the 5’-overhangs.  For In-Fusion cloning, inserts are amplified by primers that 
include 15 bp of homology with the desired sites in the multiple cloning site of the vector.  The 
vector is linearized at these sites (e.g. by restriction digest), and the vector and insert are 
combined the presence of the In-Fusion enzyme.  The DNA fragments are initially associated 
non-covalently by base-pairing interactions.  The associated DNA fragments are ligated to form 
the final desired vector in bacteria following transformation of the bacteria with the DNA (Irwin 
et al., 2012). 
Transformation of Bacteria 
 The In-Fusion cloning mixture (2.5 µL) was used to transform 20 µL of XL10-Gold 
Ultracompetent Cells (Agilent Technologies), which are bacteria that can be transformed with 
high efficiency, according to the manufacturer’s instructions, except that 0.8 µL of β-
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mercaptoethanol was used per 20 µL of cells.  Briefly, XL10-Gold cells are incubated with β-
mercaptoethanol and DNA from the In-Fusion reaction.  The XL10-Gold cells are then heat-
shocked at 42 ºC for 30 sec to induce them to take up the DNA.  They are allowed to recover on 
ice for 2 min, and then they are incubated in SOC medium (Life Technologies) for 1 h at 37 ºC.  
Of the final transformation mixture, 200 µL was plated on imMedia Amp Agar (Life 
Technologies) ampicillin-containing LB-agar plates and incubated at 37 ºC overnight to allow 
for colony growth. 
Plasmid Preparation 
 A transformed bacterial colony was used to inoculate 3 mL LB medium (MP 
Biomedicals) containing ampicillin (Sigma-Aldrich) at a concentration of 50 µg/mL.  The 
miniprep culture was incubated at 37 ºC overnight while shacking at 250 rpm.  Following the 
incubation, 1.5 mL of the culture was stored at 4 ºC for future use, and the other 1.5 mL of the 
culture was subjected to centrifugation at 11,000 × g for 30 s.  A miniprep purification was 
performed on the cell pellet using the NucleoSpin Plasmid QuickPure kit (Macherey-Nagel), 
which purifies DNA in manner similar to the DNeasy Tissue Kit described above, according to 
the manufacturer’s instructions.  The purified plasmids were sequenced using the Genewiz 
sequencing service to confirm successful cloning.  In order to obtain a larger quantity of plasmid 
DNA for future experiments, a midiprep culture of 80 mL LB medium containing ampicillin at a 
concentration of 50 µg/mL was inoculated with 1.5 mL of the reserved miniprep culture and 
incubated at 37 ºC overnight while shacking at 250 rpm.  Following the incubation, the culture 
was subjected to centrifugation at 5,000 × g for 15 min at 4 ºC.  A midiprep purification was 
performed on the cell pellet using the NucleoBond Xtra Midi Plus EF kit (Macherey-Nagel), 
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which purifies DNA in manner similar to the DNeasy Tissue Kit described above, according to 
the manufacturer’s instructions. 
Site-Directed Mutagenesis 
 Site-directed mutagenesis was performed using the QuikChange Lightning Site-Directed 
Mutagenesis Kit (Agilent Technologies), according to the manufacturer’s instructions.  Briefly, 
PCR is performed on the desired circular vector with primers containing the desired mutation.  
The PCR replicates both strands of the vector, except that the strands produced by PCR contain 
the desired mutation.  The two strands can anneal, but contain a nick on each strand.  Thus, a 
mutated circular piece of DNA with offset ssDNA nicks present on either strand is produced.  
The original (unmutated) template vector, which was originally purified by midiprep purification 
from bacteria, had undergone DNA methylation in the bacteria.  However, the new mutated 
vector produced by PCR is not methylated.  The original template vector can be digested by the 
restriction enzyme DpnI, which digests only methylated DNA, leaving the new mutated vector 
intact.  The mutated vector is transformed into XL-10 Gold cells as described above, and the 
ssDNA nicks are ligated in the bacteria.  Primers used for site-directed mutagenesis are listed in 
Table 2.3. 
Table 2.3.  Primers for Site-Directed Mutagenesis of the Proximal PAS in the Human Tau 3’-UTR. 
Construct Orientation Sequence (5’ to 3’) 
Tau3UTR_long 
 
 
Forward TTTCCAAATTGATGGGTGGGCTAGTAATCAAATATTTAAAAAA
AAACATTCAAAAACA 
Tau3UTR_long Reverse TGTTTTTGAATGTTTTTTTTTAAATATTTGATTACTAGCCCACC
CATCAATTTGGAAA 
 
Transfection of Cultured Cells 
 M17D and HEK 293 cells were transfected at 80-90% confluency using Lipofectamine 
2000 (Life Technologies), and differentiated SH-SY5Y cells were transfected at 80-90% 
	  	  32 
confluency using Lipofectamine LTX (Life Technologies) according to the manufacturer’s 
protocols.  Plasmids were transfected at 1 µg per well of a 24-well plate. 
Dual Luciferase Assay 
 Firefly and Renilla luciferase activity was determined using the Dual-Luciferase Reporter 
Assay System (Promega), which uses luciferin as a substrate for firefly luciferase, and 
coelenterazine as a substrate for Renilla luciferase, according to the manufacturer’s instructions.  
Luminescence signal was measured using a Synergy H1 Hybrid Multi-mode Microplate Reader 
(BioTek). 
Total RNA Isolation 
 Total RNA was isolated using the Nucleospin RNA II kit (Macherey-Nagel), according 
to the manufacturer’s protocol.  The RNA isolation by the Nucleospin RNA II kit works 
according to a similar principle to that of the DNeasy Tissue Kit described above, except that 
RNA is adsorbed to the membrane instead of DNA.   The total RNA was DNaseI-treated using 
the TURBO DNA-free Kit (Life Technologies) to remove any contaminating DNA. 
Quantitative PCR 
 RNA was reverse transcribed to cDNA using Double Primed RNA to cDNA EcoDry 
Premix (Clontech) according to the manufacturer’s instructions.  Quantitative PCR (qPCR) was 
performed using TaqMan chemistry (Life Technologies) using the absolute quantification 
method of analysis on the ViiA 7 Real-Time PCR System (Life Technologies).  In qPCR using 
TaqMan chemistry, a modified PCR reaction is performed.  In addition the forward and reverse 
primers used in traditional PCR, a third oligonucleotide, known as the TaqMan probe, is used.  
The TaqMan probe anneals to the target DNA sequence between the forward and reverse 
primers.  A fluorophore is covalently attached to the 5’-end of the TaqMan probe, while a 
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quencher is attached to the 3’-end of the probe.  The fluorphore and quencher are in close 
proximity while attached to the probe, and the quencher quenches the fluorescence of the 
fluorophore.  The heat-stable Taq DNA polymerase used in the qPCR reaction has intrinsic 5’-
to-3’ exonuclease activity, and when it encounters the TaqMan probe annealed to the template as 
the polymerase is replicating the DNA in the 5’-to-3’ direction, the 5’-to-3’ exonuclease activity 
of the polymerase degrades the TaqMan probe, releasing the fluorophore and quencher into the 
solution.  No longer covalently attached by the probe, the fluorophore and quencher are no 
longer in sufficient proximity for the fluorescence to be quenched.  The fluorescence signal from 
the fluorphore can then be detected by the qPCR instrument.  The fluorescence signal is 
proportional to the amount of DNA template present in the reaction.  A variety of methods for 
analyzing the qPCR results have been developed.  In these studies, the absolute quantification 
method was used.  A serial dilution of a DNA standard of known copy number is included on the 
qPCR plate for each probe used.  From this, a standard curve can be generated to allow the 
determination of the target copy number in the unknown samples.  The pmirGLO vector was 
used as a standard for the firefly luciferase gene luc2 and the Renilla luciferase gene hRluc.  
Custom TaqMan probes (Life Technologies) were designed for the luc2 and hRluc genes in the 
pmirGLO vector (Table 2.4). 
Statistical Analysis 
 Data are presented as a mean of biological replicates, and variation is indicated as the 
SEM.  Comparisons were conducted using a one-way ANOVA followed by a Tukey test to 
correct for multiple comparisons. 
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Table 2.4.  Custom TaqMan Gene Expression Assay Probes. 
Target Oligonucleotide Type Sequence (5’ to 3’) 
Firefly luciferase (luc2) Forward Primer GCGCAGCTTGCAAGACTATAAG 
 Reverse Primer TTGTCGATGAGAGTGCTCTTAGC 
 TaqMan Probe CTGGTGCCCACACTAT 
Renilla luciferase (hRluc) Forward Primer CCTCCTGGATCACTACAAGTACCT 
 Reverse Primer GTGGCCCACAAAGATGATTTTCT 
 TaqMan Probe CAGCAGCTCGAACCAA 
 
Results 
 In order to define the 3’-ends of the human tau 3’-UTR isoforms, total RNA from human 
frontal cortex was subjected to 3’-RACE.  The 3’-RACE products were sequenced and aligned 
with the human MAPT gene to identify the site where cleavage and polyadenylation occur for 
each isoform.  The short 3’-UTR isoform is 256 nt long beginning at the first nucleotide after the 
stop codon, has a canonical AATAAA PAS, and has a canonical CA cleavage site (Figure 2.2A).  
The long tau 3’-UTR isoforms is 4163 nt in length, has a canonical AATAAA PAS, and has a 
non-canonical TA cleavage site (Figure 2.2B).  These data were used to clone the wild-type and 
short tau 3’-UTR sequences into the pmirGLO luciferase reporter construct.  A construct that 
expresses the long only tau 3’-UTR was made by mutating the proximal tau PAS (A233C) in the 
wild-type tau 3’-UTR constructs so that cleavage and polyadenylation do not occur at this site.  
A schematic of these constructs is shown in Figure 2.2C. 
 These constructs were used to investigate the potential role of alternative polyadenylation 
in regulating tau expression.  As a pilot experiment, the empty pmirGLO vector, the wild-type 
tau 3’-UTR construct (Tau3UTR_WT), the short tau 3’-UTR construct (Tau3UTR_short), or the 
long tau 3’-UTR construct (Tau3UTR_long) was transfected into HEK 293 cells because of their 
ease of transfection.  After 48 h, the transfected cells were lysed, and the lysate was subjected to 
a dual luciferase assay for firefly luciferase and Renilla luciferase activity.  Firefly luciferase  
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Human MAPT
3'-RACE Long
4120 4130 4140 4150 4160 4170
G T T GC T GT AAAAGT GAAT T T GGAAAT AAAGT T AT T AC T C T GAT T AAAT AAGGT C T C C A
GT T GC T GT AAAAGT GAAT T T GGAAAT AAAGT T AT T AC T C T GAT T AAAAAAAAAAAAA -
Human MAPT
3'-RACE Short
220 230 240 250 260
T T GAT GGGT GGGC T AGT AAT AAAAT AT T T AAAAAAAAAC AT T C AAAAAC AT GG
T T GAT GGGT GGGC T AGT AAT AAAAT AT T T AAAAAAAAAC AT T C AAAAAAAAAA
C
Figure 2.2.  Human Tau 3’-UTR Isoforms.  A and B.  ClustalW alignment of the 3’-
UTR of the human MAPT gene with (A) the short 3’-RACE product and (B) the long 3’-
RACE product.  The numbering begins at the first nucleotide of the human tau 3’-UTR.  
The PAS is indicated by a dashed line, and the cleavage site is indicated by a solid line.  
The “C” above position 233 in A. denotes the position mutated in the PAS to produce the 
Tau3UTR_long construct (A233C mutation).  C. Diagram of the luciferase reporter 
constructs containing wild-type (WT), long, and short tau 3’-UTRs. 
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activity for a sample was normalized by dividing by the Renilla luciferase activity for that 
sample.  The pilot experiment revealed a statistically significant difference in the expression of 
the Tau3UTR_short and Tau3UTR_long constructs (Figure 2.3), suggesting alternative 
polyadenylation may be a mechanism of regulating tau expression. 
 In order to study this phenomenon in a system more relevant to the nervous system, the 
experiment was repeated in two human neuroblastoma cells lines, M17D and differentiated SH-
SY5Y cells.  For these experiments, in addition to examining the expression of the luciferase 
reporters at the protein level by the dual luciferase assay, the mRNA expression level was 
determined by qPCR.   In agreement with the results from HEK 293 cells, these experiments 
revealed that the expression of the short isoform construct is significantly higher than that of the 
long isoform construct in both neuroblastoma cell lines at the level of both protein and mRNA 
(Figure 2.4).  In general, the wild-type tau 3’-UTR reporter, which contains both PASs, had 
intermediate expression levels (Figure 2.4). 
Discussion 
Tau transcripts approximately 2 kb and 6 kb in length, corresponding to the short and 
long tau 3’-UTR isoforms, respectively, have been described (Goedert et al., 1988; Poorkaj et al., 
2001; Wang et al., 1993).  Additionally, sequence analysis of the MAPT gene from human, 
mouse, and rat has revealed potential PASs in the tau 3’-UTR from these species (Poorkaj et al., 
2001).  However, the 3’-RACE data presented here represents the first report of the sequence of 
both human tau 3’-UTR isoforms at nucleotide resolution.  The PAS for the short tau 3’-UTR 
identified by 3’-RACE (Figure 2.2A) corresponds to the PAS predicted by Poorkaj and 
colleagues (Poorkaj et al., 2001).  Poorkaj and coworkers identified two possible PASs for the 
long tau 3’-UTR isoform, one being an AATAAA motif and the other being an ATTAAA motif  
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Figure 2.3. Expression of Human Tau 3’-UTR Isoforms is Differentially Regulated in 
HEK 293 Cells. The indicated constructs were transfected into HEK 293 cells. After 48 h, 
luciferase expression was determined by dual luciferase assay.  n =  3 biological replicates. 
Error bars represent SEM. Data analyzed by one-way ANOVA followed by Tukey test.  *, 
adjusted p < 0.05. Note that all comparisons with pmirGLO reached statistical significance, 
but this is not indicated on the graph for clarity.  
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Figure 2.4. Expression of Human Tau 3’-UTR Isoforms is Differentially Regulated in 
Human Neuroblastoma Cells. The indicated constructs were transfected into (A and C) 
M17D cells or (B and D) differentiated SH-SY5Y cells. After 48 h, luciferase expression was 
determined by (A and B) dual luciferase assay or (C and D) qPCR. For each experiment, n =  
3 biological replicates. Error bars represent SEM. Data analyzed by one-way ANOVA 
followed by Tukey test.  *,**,***,**** adjusted p < 0.05, 0.01, 0.001, 0.0001, respectively. 
Note that in A, comparisons of pmirGLO with Tau3UTR_WT and Tau3UTR_long reached 
statistical significance and in B, all comparisons with pmirGLO reached statistical 
significance.  These comparisons are not indicated on the graph for the sake of clarity.  
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in humans (Poorkaj et al., 2001).  The 3’-RACE data unequivocally show that the PAS used for 
the long human tau 3’-UTR is the AATAAA motif, as the cleavage site is the TA of the 
ATTAAA motif (Figure 2.2B). 
Alternative polyadenylation is an important mechanism of regulating gene expression.  
Alternative transcripts produced by APA may have different stabilities, translational efficiencies, 
and/or localizations (Shi, 2012).  Despite the knowledge that tau undergoes APA (Goedert et al., 
1988; Poorkaj et al., 2001; Wang et al., 1993) and the recognition that APA is a key regulator of 
gene expression (Shi, 2012), the functional consequences of the APA of tau has not previously 
been studied.  The present study is the first to demonstrate that the expression of the two 3’-UTR 
isoforms resulting from the APA of tau is differentially regulated.  In all three cell lines tested, 
the protein expression from the short tau 3’-UTR isoform construct is higher than that of the long 
tau 3’-URT construct (Figures 2.3 and 2.4).  Similarly, in both cell lines in which mRNA 
expression was examined, the mRNAs were higher for the short tau 3’-UTR construct than the 
long tau 3’-UTR construct (Figure 2.4).  These results are consistent with previous reports that 
short 3’-UTRs are associated with higher expression than their long 3’-UTR counterparts (Mayr 
and Bartel, 2009; Sandberg et al., 2008).  The results presented here suggest that the APA of 
human tau plays a role in regulating its expression. 
While these results provide valuable insights into an unexplored aspect of tau biology, 
there are some limitations of these studies.  The functional studies were performed using 
luciferase reporter constructs, and while these constructs allow for easy experimental 
manipulation, they lack the endogenous tau promoter.  If expression from the luciferase reporter 
construct is substantially higher than that of the endogenous tau gene, the overexpression of the 
constructs may produce transcripts in vast excess relative to the trans-factors responsible for the 
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regulation of endogenous tau expression via its 3’-UTR.  If this were to occur, the expression 
pattern of the constructs may differ substantially from that of the endogenous tau 3’-UTR 
isoform transcripts.  Another limitation of these experiments is that they do not examine the 
stability and translational efficiency of the two tau 3’-UTR isoforms.  While differences in the 
levels of both mRNA and protein are seen when comparing the two isoforms (Figure 2.4), it is 
not possible with the experimental design employed here to determine if these differences are 
due solely to differences in stability or if differences in translational efficiency are also involved.  
Despite the limitations of the present study, the consistency among different cell types and at the 
protein and mRNA levels is reassuring, as is the fact that the results are in agreement with 
previously reported patterns of expression from other short and long 3’-UTR isoforms (Mayr and 
Bartel, 2009; Sandberg et al., 2008). 
The results presented here provide a novel and fundamental insight into tau biology:  
APA is a mechanism of regulating tau expression.  This observation suggests several avenues of 
follow up studies.  The differential expression of the two tau 3’-UTR isoforms is most likely due 
to the presence of one or more cis-elements present in the long tau 3’-UTR isoform but absent in 
the short tau 3’-UTR.  The effect of the regulatory cis-element(s) would be mediated by trans-
factors.  Chapters 3 and 4 of this dissertation are focused on the identification of some of these 
regulatory cis-elements and trans-factors, respectively.   
The finding that APA can regulate tau expression also raises additional questions for 
future study.  For example, in what contexts is the regulatory effect of APA on tau important?  In 
general, APA is spatially and temporally regulated, reflecting the need for differential gene 
expression profiles during different physiological states (Shi, 2012).  Examples of this that are 
particularly relevant for tau include a general trend toward expression of shorter 3’-UTR 
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isoforms following neuronal activity (Flavell et al., 2008) and a general trend toward expression 
of longer 3’-UTR isoforms during the process of development (Ji et al., 2009).  In addition to 
physiological processes, such as those discussed above, changes in APA have been associated 
with diseased states.  The most studied disease in which APA patterns change is cancer, in which 
there is a general upregulation of short 3’-UTR isoforms (Fu et al., 2011; Lin et al., 2012; Mayr 
and Bartel, 2009).  A global trend toward increased expression of short 3’-UTR isoforms has 
also been described in cardiac hypertrophy (Park et al., 2011).  One report describes an increase 
in the short tau 3’-UTR in the frontal cortex of AD patients (Goedert et al., 1988), but the 
identity of the isoform was unclear at the time.  There have been no follow-up studies to confirm 
these observations.  These topics for future study will be discussed further in Chapter 5. 
In addition to influencing the stability and/or translational efficiency of a transcript, 3’-
UTRs can also regulate the subcellular localization of transcripts (Shi, 2012).  Previous work has 
demonstrated that the rat tau 3’-UTR contains an axonal localization signal (Aronov et al., 2001; 
Behar et al., 1995).  However, this axonal localization signal is not well-conserved in humans 
(Aronov et al., 2001; Poorkaj et al., 2001).  The human tau 3’-UTR may contain a different 
axonal localization signal, and this should be investigated further.  This topic will be discussed 
further in Chapter 5. 
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Chapter 3 
Identification of cis-Elements Involved in the Function of the Human Tau 3’-Untranslated 
Region 
 
 
 
 
 
 
 
 
 
 
Experimental contributions to this chapter:  John Dickson performed the cloning of the tau 
3’-UTR deletion constructs, transfection of the tau 3’-UTR deletion constructs into HEK 293 and 
differentiated SH-SY5Y cells and subsequent luciferase assay, transfection of the tau 3’-UTR 
fragment constructs into M17D and differentiated SH-SY5Y cells and subsequent luciferase 
assay.  Carla Kruse, a master’s degree student from the University of Southern Denmark, 
Odense, Denmark, cloned the approximately 1,000 bp human tau 3’-UTR fragments into the 
pmirGLO vector under the supervision of John Dickson.  Daniel Montagna, an undergraduate 
student at the College of Wooster, Wooster, OH, performed the transfection of the approximately 
1,000 bp human tau 3’-UTR fragment constructs into HEK 293 cells and subsequent luciferase 
assay under the supervision of John Dickson. 
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Introduction 
 The finding that the expression of the short and long tau 3’-UTR isoforms of humans is 
differentially regulated suggests that the long isoform contains one or more cis-element(s) that 
are responsible for this differential regulation since the sequence of the short tau 3’-UTR isoform 
is also in the long isoform.  A logical follow-up study to these observations is to identify the 
regulatory cis-element(s). 
 A number of regulatory sequences have been identified in 3’-UTRs.  One of the best-
studied cis-element of 3’-UTRs is the AU-rich element (ARE), which is generally between 50 to 
150 nt long.  Several occurrences of the pentanucleotide AUUUA are often found in these 
regions.  The ARE is often involved in regulating the stability of mRNA, though they have been 
reported to affect translation in some instances also (Barrett et al., 2012).  In some cases, AREs 
decrease gene expression, while in other cases they increase it. The effect of AREs on the 
expression of a particular gene may depend on which ARE-binding proteins bind that site 
(Knapinska et al., 2005). 
 Regulatory cis-elements need not have particular motifs in the primary structure of the 
mRNA.  A cis-element in the 3’-UTR of IL-2, IL-6, and G-CSF consists of a stem-loop structure 
that destabilizes the transcript.  Mutation of the cis-element in a way that preserves the stem-loop 
allows it to retain its destabilizing activity, whereas mutations that disrupt the stem loop cause it 
to loose its destabilizing activity.  This cis-element is known as a stem-loop destabilizing 
element (SLDE) (Brown et al., 1996). 
 While some cis-elements have been identified in the rodent tau 3’-UTR (Aronov et al., 
1999; Atlas et al., 2007), the findings in the rodent tau 3’-UTR may not be easily applied to the 
human tau 3’-UTR because it is not well-conserved with rodents (Poorkaj et al., 2001).  In this 
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chapter, an unbiased approach to identifying regulatory cis-elements in the human tau 3’-UTR is 
presented. 
Methods 
 The methods used were generally those described in Chapter 2.  The main exceptions are 
as follows.   The human tau 3’-UTR deletions and fragment constructs were cloned into the 
pmirGLO vector.  Primers used in the cloning of the human tau 3’-UTR deletion constructs are 
presented in Table 3.1, and primers used in the cloning of the human tau 3’-UTR fragment 
constructs are presented in Table 3.2.  For statistical analyses, comparisons were conducted using 
a one-way ANOVA followed by Dunnett’s test to correct for multiple comparisons. 
Results 
 In order to identify regulatory cis-elements in the human tau 3’-UTR, two unbiased 
approaches were taken.  First, a series of tau 3’-UTR luciferase reporter constructs with 
sequential deletions, each approximately 500 bp long, along the length of the human tau 3’-UTR 
were made.  The general approach to making these deletions constructs is outlined in Figure 3.1.  
These constructs were transfected into HEK 293 and differentiated SH-SY5Y cells.  After 48 h, 
the cells were lysed, and a dual luciferase assay was performed.  In both cell lines, deletion 
constructs Δ986-1479 and Δ3501-4000 consistently showed significantly increased normalized 
luciferase activity compared with the Tau3UTR_WT construct (Figure 3.2).  Additionally, a 
significantly increased normalized luciferase activity compared with the Tau3UTR_WT 
construct was seen with construct Δ4001-4465 in HEK 293 cells (Figure 3.2A) and with 
constructs Δ2588-3000 and Δ3001-3500 in differentiated SH-SY5Y cells (Figure 3.2B).  Thus, 
several regions that may contain regulatory cis-elements were identified with these experiments.  
However, one caveat to this approach is that it may unintentionally create an artificial regulatory  
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Table 3.1.  Primers Used in the Cloning of Human Tau 3’-UTR Deletion Constructs. 
Construct Tau 3’-UTR 
Location 
Orientation Sequence (5’ to 3’) 
Δ1-480 481-505 Forward GCTCGCTAGCCTCGAGCGATGTCAACCTTGTGTGA
GTGTGA 
Δ1-480 4451-4465 Reverse ATGCCTGCAGGTCGACTGGTGCCGGTCTTGC 
Δ481-984 1-15 Forward GCTCGCTAGCCTCGAGTCAGGCCCCTGGGGC 
Δ481-984 466-480/ 
985-999 
Reverse AGCCCTAAAGTCCCATCTGCCTGTGGCTCC 
Δ481-984 985-1009 Forward TGGGACTTTAGGGCTAACCAGTTCT 
Δ481-984 4451-4465 Reverse ATGCCTGCAGGTCGACTGGTGCCGGTCTTGC 
Δ986-1479 1-15 Forward GCTCGCTAGCCTCGAGTCAGGCCCCTGGGGC 
Δ986-1479 962-985/ 
1480-1494 
Reverse TCCATGTCAACAAGGAGGTCTGCAAAGTGGCCAAA
ATCA 
Δ986-1479 1480-1502 Forward CCTTGTTGACATGGAGAGAGCCC 
Δ986-1479 4451-4465 Reverse ATGCCTGCAGGTCGACTGGTGCCGGTCTTGC 
Δ1479-2015 1-15 Forward GCTCGCTAGCCTCGAGTCAGGCCCCTGGGGC 
Δ1479-2015 1458-1479/ 
2016-2030 
Reverse ACACAGGCCACACGACAGAAACACCTAGGGTCAC
AGC 
Δ1479-2015 2016-2035 Forward TCGTGTGGCCTGTGTGGTGC 
Δ1479-2015 4451-4465 Reverse ATGCCTGCAGGTCGACTGGTGCCGGTCTTGC 
Δ2001-2587 1-15 Forward GCTCGCTAGCCTCGAGTCAGGCCCCTGGGGC 
Δ2001-2587 1981-2000/ 
2588-2602 
Reverse GTCAGCGGGCTGAGGTGAGAGACACCTCGTGAGGG 
Δ2001-2587 2588-2607 Forward CCTCAGCCCGCTGACCTTGC 
Δ2001-2587 4451-4465 Reverse ATGCCTGCAGGTCGACTGGTGCCGGTCTTGC 
Δ2588-3000 1-15 Forward GCTCGCTAGCCTCGAGTCAGGCCCCTGGGGC 
Δ2588-3000 2569-2587/ 
3001-3015 
Reverse CAAGAACTTCAGGAATGCTCTGGTCAAGGCTTTG 
Δ2588-3000 3001-3020 Forward TTCCTGAAGTTCTTGTGCCC 
Δ2588-3000 4451-4465 Reverse ATGCCTGCAGGTCGACTGGTGCCGGTCTTGC 
Δ3001-3500 1-15 Forward GCTCGCTAGCCTCGAGTCAGGCCCCTGGGGC 
Δ3001-3500 2984-3000/ 
3501-3515 
Reverse AGGGCCTCTAACTCCGAGGAACCGAGGTGCGT 
Δ3001-3500 3501-3519 Forward GGAGTTAGAGGCCCTTGGG 
Δ3001-3500 4451-4465 Reverse ATGCCTGCAGGTCGACTGGTGCCGGTCTTGC 
Δ3501-4000 1-15 Forward GCTCGCTAGCCTCGAGTCAGGCCCCTGGGGC 
Δ3501-4000 3485-3500/ 
4001-4015 
Reverse ATTACCGAAGAAATCGTGGCTGCTCCCTCCC 
Δ3501-4000 4001-4023 Forward GATTTCTTCGGTAATTCTGAGGG 
Δ3501-4000 4451-4465 Reverse ATGCCTGCAGGTCGACTGGTGCCGGTCTTGC 
Δ4001-4465 1-15 Forward GCTCGCTAGCCTCGAGTCAGGCCCCTGGGGC 
Δ4001-4465 3983-4000 Reverse ATGCCTGCAGGTCGACATGGGACTTGCAAGTGCC 
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Table 3.2.   Primers Used in the Cloning of Human Tau 3’-UTR Fragment Inserts. 
Construct Tau 3’-UTR 
Location 
Orientation Sequence (5’ to 3’) 
1-960 1-15 Forward GCTCGCTAGCCTCGAGTCAGGCCCCTGGGGC 
1-960 939-960 Reverse ATGCCTGCAGGTCGACGGCAGCAGTTCCAACCTC
AGA 
954-1869 954-975 Forward GCTCGCTAGCCTCGAGTGCTGCCATGATTTTGGC
CACT 
954-1869 1846-1869 Reverse ATGCCTGCAGGTCGACTCCAACTACAACTCAACA
GGGTGC 
1845-2793 1845-1868 Forward GCTCGCTAGCCTCGAGTGCACCCTGTTGAGTTGT
AGTTGG 
1845-2793 2774-2793 Reverse ATGCCTGCAGGTCGACAGCTGCACACGAAGCTG
CCA 
2770-3729 2770-2798 Forward GCTCGCTAGCCTCGAGGGGCTGGCAGCTTCGTGT
GC 
2770-3729 3709-3729 Reverse ATGCCTGCAGGTCGACGGAGCCAGTGTGAGAGG
TGGC 
3730-4163 3730-3747 Forward GCTCGCTAGCCTCGAGAGACACACAGCCTGTGCT 
3730-4163 4133-4163 Reverse ATGCCTGCAGGTCGACTAATCAGAGTAATAACTT
TATTTCCAAATTC 
954-1136 954-975 Forward ATGCCTGCAGGTCGACTCCAACTACAACTCAACA
GGGTGC 
954-1136 1117-1136 Reverse ATGCCTGCAGGTCGACGCAGTGGCCGTGGGAAG
GAC 
1114-1279 1114-1133 Forward GCTCGCTAGCCTCGAGCCTGTCCTTCCCACGGCC
AC 
1114-1279 1259-1279 Reverse ATGCCTGCAGGTCGACACCTCCTGCAACCAACCA
GGG 
1259-1869 1259-1279 Forward GCTCGCTAGCCTCGAGCCCTGGTTGGTTGCAGGA
GG 
1259-1869 1846-1869 Reverse ATGCCTGCAGGTCGACTCCAACTACAACTCAACA
GGGTGC 
2770-3259 2770-2798 Forward GCTCGCTAGCCTCGAGGGGCTGGCAGCTTCGTGT
GC 
2770-3259 3237-3259 Reverse ATGCCTGCAGGTCGACCCTATCTAGCCCACCCAA
GGACA 
3232-3501 3232-3251 Forward GCTCGCTAGCCTCGAGGCCAGTGTCCTTGGGTGG
GC 
3232-3501 3482-3501 Reverse ATGCCTGCAGGTCGACCGTGGCTGCTCCCTCCCT
CT 
3499-3729 3499-3520 Forward GCTCGCTAGCCTCGAGACGGAGTTAGAGGCCCTT
GGGG 
3499-3729 3709-3729 Reverse ATGCCTGCAGGTCGACGGAGCCAGTGTGAGAGG
TGGC 
 
 
 
	  	  47 
Figure 3.1.  Construction of Tau 3’-UTR Deletion Mutants Using In-Fusion.  PCR was 
performed on regions of the Tau3UTR_WT construct, excluding the sequence to be deleted.  
Primers were constructed to contain 15 bp of homology between the fragments to be cloned 
using the In-Fusion kit. 
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Figure 3.2. Identification of Regulatory cis-Elements in the Human Tau 3’-UTR 
Using Deletion Constructs. The indicated constructs were transfected into (A) HEK 293 
cells or (B) differentiated SH-SY5Y cells, and after 48 h, a dual luciferase assay was 
performed. For each experiment, n = 3 biological replicates. The error bars indicate SEM. 
Data were analyzed by a one-way ANOVA followed by Dunnett’s test, compared with 
Tau3UTR_WT. *,**,***,**** adjusted p < 0.05, 0.01, 0.001, and 0.0001, respectively. 
 
 
 
 
 
 
 
 
 
 
N
or
m
al
ize
d 
Lu
cif
er
as
e A
ct
iv
ity
Ta
u3
UT
R_
W
T
Δ1
-48
0
Δ4
81
-98
4
Δ9
86
-14
79
Δ1
47
9-2
01
5
Δ2
00
1-2
58
7
Δ2
58
8-3
00
0
Δ3
00
1-3
50
0
Δ3
50
1-4
00
0
Δ4
00
1-4
46
5
0
1
2
3
4
****
****
****
N
or
m
al
ize
d 
Lu
cif
er
as
e A
ct
iv
ity
Ta
u3
UT
R_
W
T
Δ1
-48
0
Δ4
81
-98
4
Δ9
86
-14
79
Δ1
47
9-2
01
5
Δ2
00
1-2
58
7
Δ2
58
8-3
00
0
Δ3
00
1-3
50
0
Δ3
50
1-4
00
0
Δ4
00
1-4
46
5
0.0
0.5
1.0
1.5
2.0
2.5
*
** *** **
A B 
	  	  49 
cis-element by joining together sequences adjacent to either end of the deleted region.  In order 
to circumvent this potential confounder, a complementary approach of inserting sequential 
fragments of approximately 1,000 bp of the human tau 3’-UTR into the pmirGLO vector was 
used for future studies. 
 Once the human tau 3’-UTR fragments were cloned into the pmirGLO vector, these 
constructs were initially tested by transfecting them into HEK 293 cells.  After 48 h, the cells 
were lysed, and a dual luciferase assay was performed.  A statistically significant reduction in 
normalized luciferase expression compared with the empty pmirGLO vector was seen for 
constructs 954-1869 and 2770-3729 (Figure 3.3).  These results are consistent with those seen 
using the deletion fragments in HEK 293 cells (Figure 3.2A), as overlapping regions were 
identified in these complementary experiments. 
 The human tau 3’-UTR fragment constructs were then transfected into M17D cells and 
differentiated SH-SY5Y cells.  After 48 h, the cells were lysed, and a dual luciferase assay was 
performed.  In both cases, a statistically significant reduction in normalized luciferase expression 
compared with the empty pmirGLO vector was seen for constructs 954-1869 and 2770-3729 
(Figure 3.4), consistent with those results seen in HEK 293 cells (Figure 3.3).  Additionally, a 
statistically significant increase in normalized luciferase expression compared with the empty 
pmirGLO vector was seen for construct 3730-4163 in both cell lines (Figure 3.4).  For M17D 
cells, a moderate but statistically significant decrease in normalized luciferase expression 
compared with the empty pmirGLO vector was seen for construct 1-960 (Figure 3.4A). 
 For follow-up experiments to further localize the regulatory cis-elements of the human 
tau 3’-UTR, regions 954-1869 and 2770-3729 were selected since they were identified in all 
three cell lines used for the previous experiments.  Smaller sub-fragments from these regions  
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Figure 3.3. Identification of Regulatory cis-Elements in the Human Tau 3’-UTR 
Using HEK Cells. The indicated constructs were transfected into HEK 293 cells, and 
after 48 h, a dual luciferase assay was performed. For each experiment, n = 3 
biological replicates. The error bars indicate SEM. Data were analyzed by a one-way 
ANOVA followed by Dunnett’s test, compared with pmirGLO. **, adjusted p < 0.01. 
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Figure 3.4. Identification of Regulatory cis-Elements in the Human Tau 3’-UTR Using 
Neuroblastoma Cells. The indicated constructs were transfected into (A) M17D cells or (B) 
differentiated SH-SY5Y cells, and after 48 h, a dual luciferase assay was performed. For 
each experiment, n = 3 biological replicates. The error bars indicate SEM. Data were 
analyzed by a one-way ANOVA followed by Dunnett’s test, compared with pmirGLO. 
*,**,***,****, adjusted p < 0.05, 0.01, 0.001, and 0.0001, respectively. 
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were inserted into the pmirGLO vector, and these constructs were transfected into M17D cells.  
After 48 h, the cells were lysed, and a dual luciferase assay was performed.  For sub-fragments 
of the 954-1869 region, a statistically significant reduction in normalized luciferase expression 
compared with the empty pmirGLO vector was seen for constructs 1114-1279 and 1259-1869 
(Figure 3.5A).  For the sub-fragments of the 2770-3729 region, the normalized luciferase activity 
of sub-fragments 2770-3259 and 3499-3729 was significantly decreased compared to empty 
pmirGLO vector, whereas the normalized luciferase activity of sub-fragment 3232-3501 was 
significantly increased (Figure 3.5B). 
Discussion 
The experiments presented here are the first reported to systematically search for 
regulatory cis-elements in the human tau 3’-UTR.  A 91 nt fragment from the rat tau 3’-UTR has 
been identified (Behar et al., 1995), and it has been found to play a role in regulating the stability 
(Aranda-Abreu et al., 1999; Aronov et al., 1999), translational efficiency (Atlas et al., 2004; 
2007), and axonal localization (Aronov et al., 2001; Behar et al., 1995).  The embryonic lethal 
abnormal vision (ELAV)-like protein HuD binds a 21 nt uridine rich region within the larger 91 
nt fragment (Aranda-Abreu et al., 1999).  The 91 nt region is not well-conserved between rats 
and humans (Poorkaj et al., 2001).  A 600 nt fragment of the rat tau 3’-UTR has been found to 
contain a binding site for the insulin-like growth factor mRNA binding protein 1 (IMP1); 
however, since the binding site could not be further localized, Atlas and colleagues concluded 
that the binding of IMP1 to the rat tau 3’-UTR may be conformation-specific rather than 
sequence-specific (Atlas et al., 2007).   It is currently not possible to determine how conserved 
this putative IMP1 binding structure is between rats and humans because the binding site of 
IMP1 has not been further characterized.  Since previous studies of the rat tau 3’-UTR cannot  
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Figure 3.5. Further Localization of Regulatory cis-Elements in the Human Tau 3’-UTR. 
The indicated constructs were transfected into M17D cells, and after 48 h, a dual luciferase 
assay was performed. For each experiment, n = 3 biological replicates. The error bars indicate 
SEM. Data were analyzed by a one-way ANOVA followed by Dunnett’s test, compared with 
pmirGLO. *,**,****, adjusted p < 0.05, 0.01, and 0.0001, respectively. A. Sub-fragments of 
954-1869.  B. Sub-fragments of 2770-3729. 
	  	  54 
necessarily be used to predict the regulatory cis-elements in the human tau 3’-UTR, a systematic 
approach to identifying regulatory cis-elements in the human tau 3’-UTR is a worthwhile 
endeavor. 
Through the use of two complementary approaches and multiple cell lines, several 
regions of the human tau 3’-UTR containing putative regulatory cis-elements have been 
identified.  Each cell type studied had a specific expression pattern of the luciferase reporter 
constructs tested.  This may be due to the cell type-specific presence or absence of trans-factors 
that bind the cis-elements.  Despite the differences among the expression patterns of the cells, 
there were some commonalities among them. The data from the various approaches and cell 
lines are consistent with the presence of repressive cis-elements in the regions of 954-1869 and 
2770-3729.  Therefore, these regions were chosen for further study. Several luciferase reporter 
constructs containing sub-fragments of these regions were found to contain regulatory cis-
elements, most of which are repressive (Figure 3.5).  The presence of several repressive cis-
elements in the long tau 3’-UTR isoform is consistent with the observations from Chapter 2 that 
the expression of the long tau 3’-UTR is repressed compared to the short tau 3’-UTR.  While the 
studies with the sub-fragment constructs were informative in further localizing the regulatory cis-
elements, they do not sufficiently identify the exact cis-elements or the trans-factors that bind 
them.  Additional studies have identified one of the cis-elements and its corresponding trans-
factor, and these studies are discussed in Chapter 4.  Future experiments are required to further 
characterize the other cis-elements in the human tau 3’-UTR, which will be discussed in Chapter 
5. 
While the use of luciferase reporter constructs to identify regulatory cis-elements in the 
human tau 3’-UTR provides for an easily manipulated and analyzed experimental system, it also 
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comes with limitations.  As discussed in Chapter 2, overexpression from the constructs may 
produce transcripts in excess of the trans-factors present in the cell types used.  In cases where 
this occurs, it may not be possible to detect the presence of regulatory cis-elements that bind to 
trans-factors that are limiting.  In experiments performed with fragment insert constructs 
(Figures 3.3, 3.4, and 3.5), they are compared with the empty pmirGLO construct in statistical 
analyses.  The empty pmirGLO construct would produce a firefly luciferase transcript with a 
very short 3’-UTR, consisting primarily of the multiple cloning site.  In contrast, the fragment 
constructs contain inserts in the multiple cloning site from the human tau 3’-UTR that produce 
firefly luciferase transcripts with 3’-UTRs that can be several hundred nucleotides long.  Thus, if 
the length of the 3’-UTR alters expression of the transcripts in a sequence-independent manner, 
this could confound the results.  In the case of the experiments presented here, this does not 
appear to be a factor, as inserts with similar lengths can have different expression patterns 
compared with the empty pmirGLO vector.  Another limitation is that the approach of using 
successively smaller fragments to localize cis-elements does not identify the type of cis-element 
per se or suggest possible trans-factors that bind it.  Additional studies are needed in order to 
accomplish this, and these are discussed further in Chapter 5. 
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Chapter 4 
miR-34 Family Members Regulate Tau Expression via a Binding Site in the Tau 3’-
Untranslated Region 
 
 
 
 
 
 
 
 
 
 
 
Experimental contributions to this chapter:  John Dickson performed co-transfections in 
M17D cells followed by luciferase assay and qPCR, performed the transfection of Pre-miRs and 
LNAs into M17D cells followed by Western blot and qPCR, and performed the alignment and 
DIANA-microT analysis of miR-34 family members.  Carla Kruse, a master’s degree student 
from the University of Southern Denmark, Odense, Denmark, working under the supervision of 
John Dickson, identified candidate miRNAs for this study, performed the initial screen of the 
candidate miRNAs in HEK 293 cells followed by luciferase assay, performed site-directed 
mutagenesis of miR-34a and miR-132 seed regions, and tested the sensitivity of the wild-type 
and mutant constructs to the miRNAs of interest in HEK 293 cells followed by luciferase assay. 
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Introduction 
 miRNAs are short endogenous RNAs that regulate gene expression, typically by binding 
the 3’-UTR of the genes (Bartel, 2004).  When the miRNA and target mRNA have extensive 
complementarity, binding of the miRNA may cause cleavage of the target mRNA.  When there 
is less complementarity, binding of the miRNA tends to result in translational repression of the 
target mRNA.  The former scenario is more common in plants, whereas the latter is more 
common in metazoans (He and Hannon, 2004).  The incomplete complementarity between 
miRNAs and target mRNAs in metazoans poses a challenge to computationally predicting 
miRNA binding sites.  However, most miRNAs have a region of complete complementarity with 
the target mRNA called the seed region, and this facilitates prediction of miRNA binding sites.  
Seed regions are found near the 5’-end of miRNAs, with nucleotides 2-7 of mature miRNAs 
forming the core of the seed region.  Canonical seed regions are 7-mers or 8-mers, formed by the 
core seed region plus nucleotides 1 and/or 8.  Several programs have been developed to 
computationally predict miRNA binding sites (Bartel, 2009). 
 Several of these programs were used to identify candidate miRNAs predicted to bind the 
human tau 3’-UTR.  Functional studies were then performed to investigate the effect of these 
miRNAs.  Ultimately, these experiments validated the miR-34a family, and miR-34a in 
particular, as miRNAs that bind the human tau 3’-UTR and regulate tau expression. 
Methods 
Prediction of miRNAs Binding the Human Tau 3’-UTR 
microrna.org (Betel et al., 2007), PicTar (Krek et al., 2005), TargetScan (Lewis et al., 
2005), and DIANA-microT (Maragkakis et al., 2009) were searched for miRNAs predicted to 
bind the human MAPT gene. 
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Cell Culture 
 Cell culture was performed as described in Chapter 2. 
Site-Directed Mutagenesis 
 Site-directed mutagenesis was performed using the QuikChange Lightning Site-Directed 
Mutagenesis Kit (Agilent Technologies) according to the manufacturer’s instructions.  Primers 
used for site-directed mutagenesis are listed in Table 4.1. 
Table 4.1.  Primers for Site-Directed Mutagenesis of miR-34a and miR-132 seed regions. 
Construct Orientation Sequence (5’ to 3’) 
954-1869_mut Forward GTTGTCTGCCGTGAGAGCCCAATGTGACCCTATACCCCTCATC
ACA 
954-1869_mut Reverse TGTGATGAGGGGTATAGGGTCACATTGGGCTCTCACGGCAGA
CAAC 
3730-4163_mut Forward GTGTATTGTGTGTTTTAACAAATGATTTACACTCTGACAAGCT
GTAAAAGTGAATTTGG 
3730-4163_mut Reverse CCAAATTCACTTTTACAGCTTGTCAGAGTGTAAATCATTTGTT
AAAACACACAATACAC 
 
Transfection of Cultured Cells 
Co-transfections were preformed at 70-80% confluency and included 200 ng plasmid and 
30 nM Pre-miR miRNA Precursor (Life Technologies) per well of a 24-well plate.  Transfection 
of oligonucleotides alone was performed at 60-70% confluency.  Transfection of Pre-miR 
miRNA Precursors was performed at a concentration of 50 nM.  Transfection of miRCURY 
LNA microRNA Inhibitors (Exiqon) was performed at a concentration of 20, 50, 60, or 100 nM 
per LNA, as indicated.  Sequences of these oligonucleotides are listed in Table 4.2. 
Dual Luciferase Assay 
The dual luciferase assay was performed as described in Chapter 2. 
Western Blot 
Cells were lysed in M-PER Mammalian Protein Extraction Reagent (Thermo Scientific) 
containing Halt Protease Inhibitor Cocktail (Thermo Scientific).  The protein in the lysates was  
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Table 4.2.  miRNA-Related Oligonucleotides. 
Oligonucleotide Sequence (5’ to 3’) 
Pre-miR Negative Control #1 
 
Proprietary (Life Technologies Catalog # AM17110) 
Pre-miR-34a-5p 
 
Proprietary (Life Technologies Catalog # PM11030) 
Pre-miR-132-3p 
 
Proprietary (Life Technologies Catalog # PM10166) 
Pre-miR-181c-5p 
 
Proprietary (Life Technologies Catalog # PM10181) 
Pre-miR-642-5p 
 
Proprietary (Life Technologies Catalog # PM11477) 
miRCURY LNA Negative Control A 
 
GTGTAACACGTCTATACGCCCA 
miRCURY LNA hsa-miR-34a-5p 
 
ACAACCAGCTAAGACACTGCC 
miRCURY LNA hsa-miR-34b-5p 
 
AATCAGCTAATGACACTGCCT 
miRCURY LNA hsa-miR-34c-5p GCAATCAGCTAACTACACTGCC 
 
quantified using the Pierce BCA Protein Assay Kit (Thermo Scientific) according to the 
manufacturer’s instructions.  For each lysate, 3 µg total protein, NuPAGE Sample Reducing 
Agent (Life Technologies), and NuPAGE LDS Sample Buffer (Life Technologies) were 
combined and heated to 70 ºC for 10 min.  The samples were subjected to lithium dodecyl sulfate 
PAGE (LDS-PAGE) on a NuPAGE Novex 4-12% Bis-Tris Gel (Life Techologies) in XT MES 
Buffer (Bio-Rad) at 200 V for 35 min.  The proteins were transferred to an Immobilon-P 
membrane (Millipore) in Novex Tris-Glycine Buffer (Life Technologies) with 20% methanol at 
180 mA for 75 min.  The blots were blocked in 5% milk in TBS with 0.1% Tween-20 (TBST) 
and probed with primary antibodies (1:12,000 dilution) for total tau (Dako), sirtuin 1 (SIRT1) 
(abcam), and GAPDH (Novus Biologicals) in 5% milk in TBST for 1 h at room temperature or 
overnight at 4 ºC.  Secondary antibodies conjugated to HRP (GE Healthcare) were used as a 
dilution of 1:8,000 in 5% milk in TBST for 1 h at room temperature.  The HRP activity was 
visualized using Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare 
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Life Sciences), which uses luminol and hydrogen peroxide in a chemiluminescent reaction 
catalyzed by HRP. 
Total RNA Isolation 
 Total RNA isolation was performed as described in Chapter 2. 
Quantitative PCR 
 Quantitative PCR was performed generally as described in Chapter 2.   For investigation 
of endogenous tau expression, TaqMan assays for total tau and GAPDH were used.  Additional 
information for Taqman assays used in these experiments is listed in Table 4.3.  Custom GeneArt 
Strings DNA Fragments (Life Technologies) were used as standards for tau and GAPDH, and 
the sequences of these standards are provided in Table 4.4. 
Table 4.3.   TaqMan Gene Expression Assay Probes. 
Target Oligonucleotide Type Sequence (5’ to 3’) 
Tau TaqMan Assay Proprietary (Life Technologies Assay ID:  
Hs00902194_m1) 
GAPDH TaqMan Assay Proprietary (Life Technologies Assay ID:  
Hs99999905_m1) 
 
Table 4.4.   Custom Standards for Absolute Quantification qPCR. 
Gene Sequence 
Tau GTAAAATCTGAGAAGCTTGACTTCAAGGACAGAGTCCAGTCGAAGATTGGGTCCC
TGGACAATATCACCCACGTCCCTGGCGGAGGAAATAAAAAGATTGAAACCCACA
AGCTGACCTTCCGCGAGAACGCCAAAGCCAAGACAGACCACGGGGCGGAGATCG
TGTACAAGTCGCCAGTGGTGTCTGGGGACACGTCTCC 
 
GAPDH AGCCCGCAGCCTCCCGCTTCGCTCTCTGCTCCTCCTGTTCGACAGTCAGCCGCATC
TTCTTTTGCGTCGCCAGCCGAGCCACATCGCTCAGACACCATGGGGAAGGTGAAG
GTCGGAGTCAACGGATTTGGTCGTATTGGGCGCCTGGTCACCAGGGCTGCTTTTA
ACTCTGGTAAAGTGGATATTGTTGCCATCAATGACCCCTTCATTGACCTCAACTAC
ATGGTTTACATGTTCCAATATGATTCCACCCATGGCAAATTCCATGGCACCGTCAA
GGCTGAGAACGGGAAGCTTGTC 
 
Statistical Analysis 
 Data are presented as a mean of biological replicates, and variation is indicated as the 
SEM.  Comparisons were conducted using an unpaired Student’s t-test.  
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Results 
 In parallel with the unbiased approach to identify regulatory cis-elements in the human 
tau 3’-UTR, a candidate-based approach to identify trans-factors that regulate tau expression via 
binding to its 3’-UTR was undertaken.  In particular, candidate miRNAs that may bind the 
human tau 3’-UTR were sought because of the availability of several online prediction tools, 
namely microrna.org (Betel et al., 2007), PicTar (Krek et al., 2005), TargetScan (Lewis et al., 
2005), and DIANA-microT (Maragkakis et al., 2009).  The initial search identified 17 candidate 
miRNAs, and the list of candidate miRNAs was narrowed to a manageable number by selecting 
those with conserved seed regions and/or previous reports of dysregulation in AD (Cogswell et 
al., 2008; Maes et al., 2009) (Table 4.5). 
 
 In order to screen the four final candidate microRNAs for functional effects on constructs 
expressing the tau 3’-UTR, HEK 293 cells were co-transfected with the Pre-miR precursor 
miRNA mimic corresponding to the candidate miRNA or a non-targeting negative control Pre-
miR and a luciferase reporter vector containing a fragment of the human tau 3’-UTR predicted to 
contain the miRNA binding site.  As a control for specificity, co-transfections of Pre-miRs and 
the empty pmirGLO vector were also performed.  In this screen, a specific reduction in the tau 
3’-UTR luciferase reporter activity, which was normalized to the Renilla luciferase control, was  
 
Table 4.5.  Candidate miRNAs Predicted to Target the Human Tau 3’-UTR. 
miRNA Prediction Program Identifying this miRNA Location of Predicted Binding Site in 3’-UTR 
hsa-miR-34a 
 
microRNA.org, PicTar, TargetScan, DIANA-microT 1172-1194 
hsa-miR-132 
 
microRNA.org, DIANA-microT 4104-4121 
hsa-miR-181c 
 
microRNA.org, DIANA-microT 4056-4074 
hsa-miR-642 DIANA-microT 4019-4036 
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Figure 4.1. Screening Candidate miRNAs for Effects on Luciferase Reporter Activity 
from Tau 3’-UTR Construct Expression. The indicated luciferase reporter constructs and 
Pre-miRs were co-transfected into HEK 293 cells. After 48 h, luciferase protein levels were 
determined by a dual luciferase assay.  For each experiment, n = 3 biological replicates. The 
error bars indicate SEM. Data were analyzed by unpaired t-test.  *,***, p < 0.05, 0.001, 
respectively.  Luciferase assays performed on lysates from cells treated with (A) Pre-miR-
34a, (B) Pre-miR-132, (C) Pre-miR-181c, and (D) Pre-miR-642. 
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observed for Pre-miR-34a and Pre-miR-132; however, no effect was seen with Pre-miR-181c or 
Pre-miR-642 (Figure 4.1).   
In a follow-up experiment, the seed regions of miR-34a and miR-132 were mutated in the 
luciferase reporter constructs by site-directed mutagenesis (Figures 4.2A & B). Co-transfection 
of Pre-miR-34a with the luciferase reporter construct containing the wild-type miR-34a binding 
site in HEK 293 cells resulted in lower normalized luciferase reporter expression compared with 
the non-targeting negative control Pre-miR (Figure 4.2C).  In contrast, the miR-34a seed region 
mutant luciferase reporter vector was insensitive to Pre-miR-34a (Figure 4.2C), demonstrating 
that miR-34a does indeed interact specifically with this seed region.  A similar experiment was 
performed with Pre-miR-132.  In this case, Pre-miR-132 repressed the expression of both the 
wild-type and mutated miR-132 seed region tau 3’-UTR luciferase reporter constructs (Figure 
4.2D), indicating that the observed effect was not due to binding of miR-132 to its predicted 
binding site in the human tau 3’-UTR.  Since these experiments identified the binding site of 
miR-34a but not miR-132, miR-34a became the focus of additional studies exploring the role of 
miRNAs in regulating tau expression. 
 In order to test the effect of miR-34a on the luciferase reporter constructs in a system 
more relevant to the nervous system, the co-transfections with Pre-miR-34a were repeated in 
M17D neuroblastoma cells.  After 48 h, the cells were lysed and a dual luciferase assay was 
performed, which yielded the same result in M17D cells (Figure 4.3A) as was seen in HEK293 
cells (Figure 4.2C).  In order to examine the effect of Pre-miR-34a on the luciferase reporters at 
the mRNA level, the co-transfections were repeated in M17D cells, and the expression of firefly 
and Renilla luciferase mRNAs was measured by qPCR.  Again, the construct with wild-type  
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Figure 4.2.  Effect of Mutating the miR-34a and miR-132 Seed Regions in Tau 3’-UTR 
Luciferase Constructs.  A and B.  Alignment of the mutated (A) miR-34a or (B) miR-132 
seed region tau 3’-UTR construct with the wild-type human MAPT sequence. The numbering 
begins at the first nucleotide of the human tau 3’-UTR.  The mutated nucleotides of the seed 
regions are underlined.  C and D.  The indicated luciferase reporter constructs and Pre-miRs 
were co-transfected into HEK 293 cells. After 48 h, luciferase expression was determined by 
a dual luciferase assay. n = 3 biological replicates.  Error bars indicate SEM.  Data analyzed 
by unpaired t-test.  *,**, adjusted p < 0.05 and 0.01, respectively.  
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Figure 4.3.  The Pre-miR-34a Mediated Repression of Expression from a Tau 3’-UTR 
Luciferase Reporter Construct is miR-34a Seed region-Dependent in M17D cells. The 
indicated luciferase reporter constructs and Pre-miRs were co-transfected into M17D cells. 
After 48 h, luciferase expression was determined at the protein level by (A) dual luciferase 
assay or at the mRNA level by (B) qPCR. For each experiment, n = 3 biological replicates.  
Error bars indicate SEM.  Data analyzed by unpaired t-test.  *,****, adjusted p < 0.05 and 
0.0001, respectively. 
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miR-34a seed region was sensitive to Pre-miR-34a, whereas the miR-34a seed region mutant was 
not (Figure 4.3B).  These results indicate that miR-34a can affect the expression of reporter 
constructs containing the miR-34a binding site at both the level of protein and mRNA.   
In order to investigate the ability of miR-34a to regulate the expression of endogenous 
tau, Pre-miR-34a or a non-targeting negative control Pre-miR was transfected into M17D cells.  
After 48 h, the cells were lysed, and a Western blot probing for total tau, SIRT1, and GAPDH 
was performed.  SIRT1 was included as a positive control, as it is a known target of miR-34a 
(Yamakuchi et al., 2008), and GAPDH was included as a loading control.  Cells transfected with 
Pre-miR-34a had reduced expression of tau and SIRT1 compared to cells transfected with the 
negative control Pre-miR (Figure 4.4A), demonstrating that miR-34a can control endogenous tau 
protein expression.  To determine the ability of endogenous miRNAs to regulate endogenous tau 
expression, locked nucleic acid (LNA) microRNA inhibitors of miR-34a, -34b, and -34c were 
transfected into M17D cells and the Western blot analysis was performed as described above. A 
combination of LNA inhibitors of all miR-34 family members was used to prevent possible 
compensation by other family members if an inhibitor of only one family member were used.  
The Western blot analysis revealed that inhibition of endogenous miR-34 family members led to 
a moderate increase in endogenous tau protein expression (Figure 4.4B).  However, no effect on 
SIRT1 was detected (Figure 4.4B).  The effect of Pre-miR-34a or LNA inhibition of miR-34 
family members on the expression of endogenous total tau mRNA in M17D cells was examined 
using qPCR, with GAPDH mRNA serving as a normalization control.  In agreement with the 
Western blot data, Pre-miR-34a reduced tau mRNA expression (Figure 4.4C), whereas inhibition 
of miR-34 family members led to an increase in tau mRNA expression (Figure 4.4D).  Taken  
 
	  	  67 
 
 
 
 





	

 







!



	






	



















!



	







"






#

  





$

!









 
82 kDa -
115 kDa -
49 kDa -
82 kDa -
115 kDa -
49 kDa -
Tau
SIRT1
GAPDH
Tau
SIRT1
GAPDH
- Control Pre-miR-34a - Control LNA-34a/b/cA
C D
B
Figure 4.4. miR-34 Family Members Regulate the Expression of Endogenous Tau. The 
indicated oligonucleotides were transfected into M17D cells.  Pre-miRs were used at a 
concentration of 50 nM.  The LNA for each of miR-34 family members had a final 
concentration of 20 nM, for a final total LNA concentration of 60 nM.  The negative control 
LNA was used at a concentration of 60 nM.  After 48 h, the cells were lysed.  A and B. 
Western blot analysis was performed using primary antibodies for tau, SIRT1, and GAPDH.  
C and D. qPCR was performed using TaqMan probes for tau and GAPDH.  For each 
experiment, n = 3 biological replicates.  Error bars indicate SEM.  Data analyzed by unpaired 
t-test.  *, adjusted p < 0.05.  
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together, these data indicate that endogenous miR-34 family members regulate tau expression at 
both the protein and mRNA levels. 
The members of the miR-34 family share a common seed region (Figure 4.5A), and 
according to the DIANA-microT database (Maragkakis et al., 2009), each member of the family 
is predicted to bind the human tau 3’-UTR (Figure 4.5B, C, & D).  However, for this study, miR-
34a is the one of most interest since it is the miR-34 family member with the highest expression 
in brain tissue (Bommer et al., 2007) and since its expression is upregulated in brain tissue 
(Cogswell et al., 2008) and blood mononuclear cells (Schipper et al., 2007) from patients with 
AD.  Therefore, the role of endogenous miR-34a in regulating endogenous tau expression was 
examined by transfecting M17D cells with 50 or 100 nM LNA inhibitor of miR-34a (LNA-34a).  
The cells were lysed 48 h after transfection, and a luciferase assay was performed as described 
above.  At a concentration of 50 nM, LNA-34a produced a modest increase in tau protein levels 
(Figure 4.6A), and the effect was more pronounced at a concentration of 100 nM (Figure 4.6B).  
Again, not effect on SIRT1 was observed (Figure 4.6).  These data suggest endogenous miR-34a 
can regulate the expression of endogenous tau.  
Discussion 
In the initial screen with commercially available precursor miRNAs (Pre-miRs) of the 
candidate miRNAs, two were found to affect the expression of a luciferase reporter construct 
containing a fragment of the human tau 3’-UTR containing the predicted miRNA binding site 
(Figure 4.1).  These two Pre-miRs, Pre-miR-34a and Pre-miR-132, did not alter the expression of 
the empty luciferase reporter vector (Figure 4.1), indicating that the observed effect was not due 
to a general alteration in gene expression.  Mutation of the miR-34a seed region in the luciferase 
reporter vector made it insensitive to Pre-miR-34a (Figure 4.2C), which is consistent with the  
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Figure 4.5.  hsa-miR-34 Family Members and Their Predicted Binding to the Human 
Tau 3’-UTR.  A.  ClustalW alignment of the hsa-miR-34 family members.  The common 
seed region is underlined.  The predicted binding of (B) hsa-miR-34a-5p, (C) hsa-miR-34b-
5p, and (D) hsa-miR-34c-5p to the human tau 3’-UTR using DIANAmicro-T is shown. 
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Figure 4.6.  miR-34a Regulates the Expression of Endogenous Tau.  A non-targeting 
negative control LNA or LNA-34a was transfected into M17D cells.  After 48 h, the cells 
were lysed. Western blot analysis was performed using primary antibodies for tau, SIRT1, 
and GAPDH.  A.  [LNA] = 50 nM.  B.  [LNA] = 100 nM. 
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mutated seed region being part of a bone fide miR-34a binding site in the tau 3’-UTR.  However, 
the luciferase reporter constructs containing both the wild-type or mutant miR-132 seed region 
were sensitive to Pre-miR-132 (Figure 4.2D), suggesting Pre-miR-132 is affecting the luciferase 
reporter via a mechanism that does not involve binding to the predicted miR-132 seed region. 
The mechanism by which Pre-miR-132 affects the expression of the 3730-4163 tau 3’-
UTR luciferase construct is currently unclear.  However, since Pre-miR-132 does not affect the 
expression of the empty pmirGLO vector (Figure 4.1B), the effect of Pre-miR-132 is most likely 
mediated by the tau 3’-UTR fragment contained in the 3730-4163 construct.  There are a couple 
of possible mechanisms by which the available data from Pre-miR-132 can be explained.  The 
first possibility is than an additional or alternative miR-132 binding site in the tau 3’-UTR 
fragment besides the one in which the seed region was mutated (Figure 4.2B).  The putative 
miR-132 binding site in which the seed region was mutated is the only miR-132 binding site in 
the human tau 3’-UTR predicted by both microRNA.org and DIANA-microT.  Thus, if an 
additional or alternative miR-132 binding site still exists in the human tau 3’-UTR, it must be an 
unconventional binding site that is not identified by these programs.  A second possibility is that 
miR-132 does not directly bind the human tau 3’-UTR but can indirectly affect the expression of 
the 3730-4163 construct.  For example, miR-132 could regulate the expression of a protein that 
directly binds the human tau 3’-UTR and regulates its expression.  In a search for miRNAs that 
regulate tau exon 10 splicing, miR-132 was found to cause a significant decrease in the 4R/3R 
ratio due to the fact that miR-132 regulates the expression of polypyrimidine tract-binding 
protein 2 (PTBP2), a splicing factor that also regulates the 4R/3R ratio (Smith et al., 2011).  
Thus, miR-132 has been demonstrated to indirectly regulate tau expression, albeit in regard to 
exon 10 splicing rather than 3’-UTR function.  Interestingly, in the study by Smith and 
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colleagues, overexpression of miR-132 was found to cause a decrease in total tau levels in 
addition to the effect on exon 10 splicing (Smith et al., 2011).  However, the mechanism by 
which miR-132 affected total tau levels was not examined. In addition to the role of PTBP2 as a 
splicing factor, it has been reported to bind the 3’-UTR of the phosphoglycerate kinase 2 
transcript in mouse testis and stabilize that mRNA (Xu and Hecht, 2007).  Therefore, it is 
conceivable that miR-132 could indirectly regulate tau expression by repressing the expression 
of a protein trans-factor that binds the human tau 3’-UTR.  Further studies are required to fully 
understand the effect of miR-132 on the 3730-4163 construct. 
In order to follow up on the results from co-transfection of wild-type or miR-34a seed 
region mutant tau 3’-UTR constructs and Pre-miR-34a in HEK 293 cells (Figure 4.2C), the co-
transfections were repeated in M17D neuroblastoma cells.  The results of the subsequent 
luciferase assay (Figure 4.3A) were consistent with those observed in HEK 293 cells (Figure 
4.2C).  Analysis of the same transfection conditions in M17D cells at the mRNA level by qPCR 
also revealed similar results (Figure 4.3C).  Taken together, these data indicate that predicted 
miR-34a binding site in the human tau 3’-UTR is a bona fide miR-34a binding site, and that 
binding of miR-34a to this site can affect the levels of both protein and mRNA from transcripts 
containing this miR-34a binding site. 
While the use of luciferase reporter constructs in studying miRNAs has utility in 
screening for miRNA binding sites and in generating seed region mutants to define the miRNA 
binding site, it is essential to test the effect of the candidate miRNA on the endogenous target 
gene of interest in order to further validate the miRNA-target mRNA pair.  To accomplish this, 
Pre-miR-34a or negative control Pre-miR was transfected into M17D cells, and tau expression 
was evaluated at the protein level by Western blot (Figure 4.4A) and at the mRNA level by 
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qPCR (Figure 4.4C).  The results were in agreement with those using the luciferase reporter 
constructs:  Pre-miR-34a causes a decrease in both tau protein and mRNA levels. 
Notably, miR-34a expression is upregulated in brain tissue (Cogswell et al., 2008) and 
blood mononuclear cells (Schipper et al., 2007) from patients with AD.  Previous studies have 
shown additional links between miR-34a and the nervous system.  miR-34a is involved in 
neuronal differentiation (Agostini et al., 2011a; Aranha et al., 2011) and neurite outgrowth 
(Agostini et al., 2011b).  In Drosophila melanogaster, deletion of the fly ortholog miR-34 causes 
accelerated brain aging and neurodegeneration (Liu et al., 2012). 
In addition to AD, miR-34a has been implicated in other diseases.  In a mouse model of 
acute myocardial infarction (AMI), miR-34a expression was significantly increased at the border 
zone of the myocardial infarction.  In mice, inhibition of miR-34a resulted in improved cardiac 
contractile function two weeks after AMI compared with mice treated with a non-targeting 
control (Boon et al., 2013).  miR-34a is a tumor suppressor, and the role of miR-34a in cancer 
has been extensively studied.  Decreased miR-34a expression, either through chromosomal 
deletion or epigenetic inactivation, has been observed in numerous types of cancer, including 
retinoblastoma, breast cancer, lung cancer, and colon cancer (Hermeking, 2010).  The most well-
characterized role of miR-34a in cancer is its involvement in the p53-miR-34a-SIRT1 positive 
feedback loop (Yamakuchi and Lowenstein, 2009).  p53 directly binds the promoter of the 
primary miR-34a (pri-miR-34a) transcript and induces its expression (He et al., 2007).  miR-34a 
directly binds the 3’-UTR of the deacetylase SIRT1 and decreases its expression (Yamakuchi et 
al., 2008).  Deacetylation of p53 by SIRT1 reduces its activity as a transcription factor for target 
genes involved in cell cycle exit or apoptosis (Vaziri et al., 2001).  Integrating these findings, 
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p53 induces miR-34a, which inhibits an inhibitor of p53 (SIRT1), thus creating a positive 
feedback loop (Yamakuchi and Lowenstein, 2009). 
In addition to miR-34a, there are two other miR-34 family members in humans:  miR-34b 
and -34c (He et al., 2007).  miR-34a is processed from a primary transcript encoded on human 
chromosome 1p36.  The other two members of the miR-34 family, miR-34b and -34c are co-
transcribed from the same locus on human chromosome 11q23 (Yang, 2011).  Because they are 
transcribed from different loci, the miR-34 family members can have different expression 
profiles, with the expression of miR-34a being highest in the brain and the expression of miR-
34b and -34c being highest in the lungs (Bommer et al., 2007).  Although miR-34b and -34c 
have been studied somewhat less extensively than miR-34a, it is known that their expression is 
reduced in several types of cancer (Hermeking, 2010). 
Shortly before the preparation of this dissertation, Wu and colleagues published a study 
focused on understanding mechanisms underlying paclitaxel resistance in gastric cancers.  They 
found that miR-34c expression was significantly reduced in paclitaxel-resistant gastric cancer, 
and in a search for a possible mechanism underlying this observation, they found that miR-34c 
regulates tau expression (Wu et al., 2013).  The miR-34c binding site in the tau 3’-UTR 
identified by Wu and colleagues (Wu et al., 2013) corresponds to the miR-34a binding site 
identified in the studies presented here (Figure 4.2A&C).  This is not surprising, given that 
members of the miR-34 family share the same seed region sequence (Figure 4.5). 
In examining the effect of inhibiting endogenous miR-34 family members on endogenous 
tau, LNA inhibitors of each miR-34 family member were included in the transfection mixture in 
order to prevent compensation for inhibition of one family member by other family members.  
Inhibition of miR-34 family members resulted in increased tau protein and mRNA levels 
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(Figures 4.4B&D).  These data, especially in conjunction with the observation by Wu and 
colleagues that treatment with Pre-miR-34c lowers tau expression(Wu et al., 2013), suggest that 
endogenous miR-34 family members regulate endogenous tau.  Since miR-34a is of particular 
interest in these studies due to its dysregulation in AD (Cogswell et al., 2008; Schipper et al., 
2007), the specific effect of inhibiting endogenous miR-34a on endogenous tau expression was 
examined.  Inhibition of miR-34a resulted in an increase in tau protein expression, with a more 
pronounced effect at an LNA concentration 100 nM compared to 50 nM (Figure 4.6).  This result 
is consistent with the hypothesis that miR-34a directly binding the tau 3’-UTR and regulates tau 
expression. 
 While the data presented here strongly suggest miR-34 family members, and miR-34a in 
particular, directly bind the human tau 3’-UTR and regulate tau expression, there are some 
limitations to these studies.  Two human cell lines, including a neuroblastoma cell line, were 
used in these experiments; however, similar experiments have not been conducted in primary 
neurons, which would be a particularly relevant cell type for these studies.  In theory, primary 
neurons from rat or mouse could be used in follow-up studies since the miR-34 family binding 
site in the human tau 3’-UTR is conserved in these species.  Since the goal of the research 
presented in this dissertation is directed toward understanding the role of the human tau 3’-UTR 
in regulating tau expression, using rodent primary neurons would carry their own limitations in 
achieving this goal.  An approach that would circumvent the caveats associated with both using 
transformed or cancerous human cell lines and using rodent primary neurons would be to use 
human neurons.  Several sources of human neurons exist, including fetal human primary 
neurons, adult human primary neurons, differentiation of human embryonic stem cells, 
differentiation of human induced pluripotent stem cells, and differentiation of adult neural stem 
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cells.  The use of these human neuronal cells come with their own challenges, depending of the 
cell type, including limited tissue available, difficulty obtaining a pure neuronal culture, the need 
to transform or differentiate cells, difficulty with reproducibility given the inherent variability in 
the human population, and ethical concerns over the use of fetal or embryonic human tissue 
(Gibbons and Dragunow, 2010). 
 Another limitation comes from the use of LNAs to inhibit the endogenous miRNAs.  A 
successful experiment of that type depends on a number of factors.  The miRNA(s) of interest 
must be expressed to a sufficient levels in the cell type used in order for inhibition of the 
miRNA(s) to have an effect on the expression of the target mRNA. The target mRNA containing 
the miRNA binding site(s) must be expressed at level such that changes in expression of target 
will be detectable by the assay method.  Additionally, the cell type used must have a transfection 
efficiency high enough for an appreciable effect of the LNA to be observed.  These factors all 
seem to have allowed for a successful experiment with regard to tau in M17D cells since an 
effect was observed (Figures 4.4 and 4.6), but the challenges associated with this method may 
explain why no effect was seen on SIRT1.  Another limitation of using LNAs, specifically in the 
case of inhibiting miR-34a alone, is that an LNA inhibitor could inhibit miRNAs besides the 
intended target.  This is particularly true if the miRNA of interest shares substantial sequence 
similarity with other miRNAs, as is the case with miR-34a and the other miR-34 family members 
(Figure 4.5A). Thus, in the experiment with miR-34a inhibition only (Figure 4.6), it is not 
possible to unequivocally conclude that the effect observed is due only to inhibition of miR-34a.  
An alternative approach that would more definitively address the role of a specific miRNA in 
regulating a target gene would be to delete the miRNA of interest from the genome entirely.  
While not a human system, mice in which miR-34a, miR-34b/c, and miR-34a/b/c have been 
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knocked out have been reported (Concepcion et al., 2012).  These would be interesting system 
for the future study of the effect of the miR-34 family on tau expression. 
Despite the limitations discussed above, the results presented in this chapter indicate the 
miR-34 family, and miR-34a specifically, play a role in regulating tau expression.  This is 
particularly interesting given that miR-34a expression is increased in AD (Cogswell et al., 2008; 
Schipper et al., 2007) and that decreased tau expression prevents the development of an AD-like 
phenotype in transgenic mouse models of AD (Ittner and Götz, 2010; Roberson et al., 2007).  
These observations raise the questions of if and how the changes in miR-34a expression relate to 
the pathophysiology of AD.  One possibility is that the upregulation of miR-34a may act as a 
compensatory mechanism to decrease the expression of tau as tau protein accumulates and 
aggregates during disease progression.  Further studies are needed to explore these questions. 
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Chapter 5 
Summary and Future Directions 
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Summary 
 The human tau 3’-UTR has not previously been studied in much detail.  Discovering the 
role the human tau 3’-UTR plays in regulating tau expression will increase the understanding of 
the basic biology of tau.  Additionally, it may eventually allow the development of novel 
strategies to modulate tau expression in humans, which may be therapeutic in Alzheimer’s 
disease.  Therefore, the studies presented here aimed to investigate the function of the human tau 
3’-UTR. 
 For the first time, the 3’-ends of the two human tau 3’-UTR isoforms were defined using 
3’-RACE, allowing the identification of the PAS and cleavage and polyadenylation site used for 
each isoform.  The studies presented here are the first to show that the expression of the tau 3’-
UTR isoforms is differentially regulated (Figures 2.3 and 2.4).  The process of APA, which 
produces the tau 3’-UTR isoforms, is a mechanism by which gene expression is temporally and 
spatially regulated (Shi, 2012).  Thus, APA may allow for the expression of appropriate levels of 
tau specific to different cell types and developmental stages.   
 Since the sequence of the short tau 3’-UTR is common to both isoforms, it is logical to 
assume that any cis-elements responsible for the differential regulation of tau expression must be 
present only in the long tau 3’-UTR isoform.  In order to identify such regulatory cis-elements, 
an unbiased search for these was undertaken, and several regions containing cis-elements were 
identified.  One of those, fragment 1114-1279 (Figure 3.5), contains the seed region for miR-34 
family members, which were subsequently shown to bind that region (Figures 4.2 and 4.3).  
Additional fragments containing cis-elements were identified, but further research is necessary in 
order to determine the minimal cis-element in these fragments and to identify the trans-factors 
that bind them. 
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 In an effort to identify a specific type of trans-factor that may bind the tau 3’-UTR, 
miRNAs, a candidate-based approach of screening selected miRNAs was undertaken in parallel 
with the unbiased screen for cis-elements.  Through these efforts, miR-34a was found to bind the 
tau 3’-UTR and regulate tau expression.  These results complement the recently published 
finding that miR-34c regulates tau expression in gastric cancer cells (Wu et al., 2013).  The miR-
34 family members have the same seed region sequence and are predicted to bind the human tau 
3’-UTR (Figure 4.5).  Wu and colleagues only examined the effect of increased miR-34c (Wu et 
al., 2013), and work present here adds to their findings by demonstrating that the inhibition of 
endogenous miR-34 family members increases endogenous tau expression (Figure 4.4).  In the 
studies presented in this dissertation, miR-34a instead of miR-34c was of particular interest 
because miR-34a is more highly expressed in the brain (Bommer et al., 2007) and because miR-
34a is upregulated in AD (Cogswell et al., 2008; Schipper et al., 2007).  The studies presented 
here are the first to show that miR-34a can regulate the expression of endogenous tau. 
 Overall, these findings suggest a model in which the miR-34 family binding site, along 
with additional regulatory cis-elements present only in the long tau 3’-UTR isoform, decrease the 
expression of the long tau 3’-UTR relative to the short one (Figure 5.1).  These findings provide 
new insights into the basic biology of tau.  They also suggest areas for additional research to 
better understand the role of APA in regulating tau expression in normal and diseased states, as 
well as to identify additional cis-elements and trans-factors involved in regulating tau 
expression. 
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Figure 5.1.  Summary of Findings.  The human tau 3’-UTR contains several regions that 
contain regulatory cis-elements.  Those that decrease expression are shown in shades of red, 
and the cis-element that enhances expression is shown in blue.  Nucleotides at the boundaries 
of regions containing cis-elements are indicated.  The numbering begins with the first 
nucleotide following the stop codon.  The human tau 3’-UTR contains two PASs (indicated by 
asterisks), and undergoes APA to produce long and short 3’-UTR isoforms.  The long isoform 
only contains the regulatory cis-elements.  The miR-34a binding site is indicated.  The 
presence of the regulatory cis-elements in the long isoform causes its expression to be reduced 
at the mRNA and protein levels, relative to the short isoform. 
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Future Directions 
Determining the Half-Lives of the Tau 3’-UTR Isoforms 
 While the results presented here reveal that the two human tau 3’-UTR isoforms are 
differentially expressed at the mRNA level (Figure 2.3), they do not specifically examine mRNA 
stability.  As a first step in investigating the possible differences in mRNA stability between the 
3’-UTR isoforms, mRNA expression of the tau 3’-UTR isoform constructs can be measured in a 
time course following inhibition of transcription by actinomycin D treatment.  These 
measurements will allow the determination of the half-lives of the constructs, which can be used 
to compare the stability of the two tau 3’-UTR isoform constructs. 
 As a follow up to this experiment, the half-lives of the endogenous tau 3’-UTR isoform 
transcripts should also be determined in a manner similar to that described above.  However, to 
allow for direct measurement of the tau 3’-UTR isoform levels, the total RNA from the time 
course should be analyzed by Northern blot. 
APA of Tau in Development 
 Global changes in APA occur during the process of development, with a trend toward 
expression of longer 3’-UTRs as development progresses (Ji et al., 2009).  Changes in alternative 
splicing of tau occur during brain development (Andreadis, 2005; Andreadis et al., 1992), so it is 
reasonable to investigate possible changes in the APA of tau during development.  Ultimately, 
definitive examination of APA in human brain development will require assessment of 3’-UTR 
isoform levels in human embryonic and fetal brain regions over the course of development and 
correlation of these levels with tau protein levels from the same tissues at the same 
developmental stages.  The expression of the tau 3’-UTR isoform mRNA and tau protein levels 
can be determined by Northern blot and Western blot, respectively.  There are a number of 
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technical challenges to this approach, including obtaining a sufficient number of samples at 
various developmental stages and obtaining mRNA of sufficient quality from postmortem human 
tissue. 
 Given the challenges associated with this definitive approach, a reasonable first step 
would be to examine APA of tau in development generally as described above but using rats 
instead of humans.  While there are clearly differences between the human and rat tau 3’-UTR, 
the rat may be a good model system to explore the role of APA of tau in development prior to 
beginning those studies in humans.  Before examining tau APA in rat development, experiments 
from Chapter 2 should be repeated using rat instead of human tau 3’-UTR isoform constructs. 
Investigating the Possible Dysregulation of the APA of Tau in Alzheimer’s Disease 
 A previously published Northern blot of tau in mRNA from frontal cortex of AD patients 
and normal controls showed an increase in the short tau 3’-UTR in AD samples (Goedert et al., 
1988).  At the time, it was not clear what the 2 kb and 6 kb bands, which are now recognized as 
the tau 3’-UTR isoforms, represented (Goedert et al., 1988; Poorkaj et al., 2001), and the finding 
was not explored further.  This is an interesting and potentially important finding since 
alterations in the expression levels of 3’-UTR isoforms produced by APA have been observed in 
some diseases.  Global dysregulation of APA has been observed in cancer (Mayr and Bartel, 
2009) and cardiac hypertrophy (Park et al., 2011).  While other explanations of the finding of tau 
3’-UTR isoform level changes are possible, one interesting hypothesis is that the APA of tau is 
dysregulated in AD. 
 At the very least, the Northern blot experiment by Goedert and colleagues (Goedert et al., 
1988) deserves repeating to determine if the results are reproducible.  However, an improved 
study design would be to globally assess APA states in the frontal cortex of AD and control 
	  	  84 
subjects using transcriptome-wide RNA sequencing (RNA-seq).  Not only would this provide 
quantitative data on the tau 3’-UTR isoform levels in AD and control frontal cortex, but it would 
also provide a context for understanding any changes seen specifically seen for tau.  That is, if a 
change in tau 3’-UTR isoform expression is seen when comparing AD and control subjects, is 
that change specific for tau, or does it occurs in the setting of global changes in APA in AD?  
Any changes in 3’-UTR isoform expression seen for tau or other key genes as identified by 
RNA-seq could be confirmed by Northern blot.  These studies may provide valuable insights into 
the possible contribution of a dysregulation of APA to AD pathogenesis. 
Investigating the Role of the Human Tau 3’-UTR in the Subcellular Localization of Tau 
 Tau mRNA is localized to the axon and soma (Litman et al., 1993), and the rat tau 3’-
UTR contains an axonal localization signal (Aronov et al., 2001).  However, the sequence of this 
axonal localization signal is not well conserved in human (Poorkaj et al., 2001).  Therefore, it is 
not currently known if the human tau 3’-UTR contains an axonal localization signal.  If it does, 
and it is found in the long 3’-UTR isoform only, the two tau 3’-UTR isoforms should show a 
different pattern of subcellular localization. 
 In order to examine this, the tau 3’-UTR isoform constructs can be transfected into 
differentiated SH-SY5Y cells, which have distinct axon-like neurites and dendrite-like neurites 
(see Appendix 1).  The subcellular localization of the firefly luciferase reporter constructs can 
then be determined by fluorescence in situ hybridization (FISH) with an antisense probe for the 
firefly luciferase coding region.  The use of the tau 3’-UTR isoform luciferase reporter constructs 
would allow the detection of transcripts containing only the 3’-UTR isoform expressed by the 
construct by allowing a probe for firefly luciferase, rather than tau, to be used.  If a difference in 
localization between the two tau 3’-UTR isoform constructs is observed, it will indicate that 
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APA is a mechanism of regulating the subcellular localization of tau, presumably via the 
inclusion or exclusion of an axonal localization signal. 
Identification of Regulatory cis-Elements in the Human Tau 3’-UTR 
 The unbiased search for regulatory cis-elements in the human tau 3’-UTR in Chapter 3 
allowed for the identification of several regions that likely contain regulatory cis-elements.  
However, with the exception of the miR-34 family member binding site, the exact locations of 
these regulatory cis-elements remain to be determined.  In order to fully identify the regulatory 
cis-elements in the human tau 3’-UTR, the process of iteratively making smaller fragments of 
regions that influence expression of the tau 3’-UTR fragment luciferase reporter constructs and 
then testing those smaller fragments to determine which one(s) contain regulatory cis-elements 
can be used.  Once the minimal cis-elements have been defined, the effect of the sequence on the 
expression of the luciferase reporter construct containing it can be determined at the mRNA level 
by qPCR.  Additionally, the cis-elements identified can be examined to determine if they match 
known binding motifs for RNA-binding proteins.  If the human tau 3’-UTR is found to contain 
an axonal localization signal, the exact location of that cis-element can be determined using the 
iterative process described above except transfecting the constructs into differentiated SH-SY5Y 
cells and analyzing by FISH rather than luciferase assay. 
Identification of Regulatory trans-Factors in the Human Tau 3’-UTR 
 In order to identify the trans-factors that bind the cis-elements determined above, a 
biotinylated RNA containing a regulatory cis-element can be used to pulldown its binding 
protein(s) from cell lysate.  The protein(s) can then be separated by LDS-PAGE and ultimately 
identified by mass spectrometry.  The ability of candidate trans-factors identified in this way to 
regulate tau expression can be tested using RNA interference (RNAi). 
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Examining the Effect of Additional miRNAs on the Human Tau 3’-UTR 
 In the screen of the candidate miRNAs, Pre-miR-132 was found to have an effect on the 
3730-4163 tau 3’-UTR fragment construct without affecting the pmirGLO construct (Figure 4.1).  
However, mutation of the predicted miR-132 seed region (which produced the 3730-4163_mut 
construct) did not change the sensitivity of the construct to Pre-miR-132 (Figure 4.2), suggesting 
that the affect is mediated through a site other than the mutated seed region.  In order to 
investigate this further, luciferase reporter constructs containing smaller subfragments of the tau 
3’-UTR from the 3730-4163_mut construct should be cloned and tested for sensitivity to Pre- 
miR-132 to further localize the sequence responsible for the effect of Pre-miR-132.  The smaller 
subfragment that is sensitive to Pre-miR-132 should be examined for a non-canonical miR-132 
binding site.  If one is found, it could be mutated to determine if that is the site Pre-miR-132 
binds.  If no obvious miR-132 binding site is found, protein trans-factors that may bind this 
region could be identified using the methods described above.  Any trans-factors identified could 
then be assessed for regulation by miR-132. 
 Additionally, other candidate miRNAs predicted to bind the human tau 3’-UTR that were 
not examined in the initial round of screening can be studied with the experiments discussed in 
Chapter 4.   
Examining the Effect of the miR-34 Family on Tau Expression in miR-34 Knockout Mice 
 In order to study the effect of miR-34 family members on tau in vivo, tau expression in 
the cortex and hippocampus of miR-34a, miR-34b/c, and miR-34a/b/c knockout mice 
(Concepcion et al., 2012) can be compared with that of wild-type littermates using Western blot 
and qPCR.  These experiments may provide valuable insights into the effect of miR-34 family 
members on tau in the intact brain. 
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Correlation of miR-34a and Tau mRNA Levels in AD and Control Brains 
 Since miR-34a can repress tau expression (Figures 4.4 and 4.6) and since miR-34a levels 
are upregulated in AD (Cogswell et al., 2008), it is possible that increased miR-34a in AD could 
lead to lower tau expression in the disease.  If this were the case, upregulation of miR-34a in AD 
may have a protective effect since reduced tau expression has been shown to ameliorate the AD 
phenotype in mouse models of AD (Ittner et al., 2010; Leroy et al., 2012; Roberson et al., 2007).  
In order to begin to investigate this possibility, miR-34a and tau mRNA expression can 
quantified and correlated in the medial frontal gyrus, hippocampus, and cerebellum, the regions 
in which miR-34a expression was found to be upregulated in AD (Cogswell et al., 2008).  
Measuring tau mRNA expression, rather than tau protein expression, in these studies is a 
reasonable choice since tau accumulates in NFTs in AD, which could confound the results.  
Additionally, correlating miR-34a and tau mRNA expression is reasonable since miR-34a affects 
tau expression at the mRNA level (Figure 4.4).  Based on the currently available evidence, which 
is described above, one would expect miR-34a expression to be higher and tau mRNA 
expression to be lower in AD brain regions compared with control brain regions.  This 
correlative study will would not provide a causal link between miR-34a and tau mRNA levels in 
AD, but it could be an informative study, especially in the context of the knowledge that miR-
34a regulates tau expression in cell culture (Figures 4.4 and 4.6). 
Conclusion 
 The studies presented here provide new insights into the biology of human tau, 
particularly the regulation of its expression by APA and miR-34a.  However, these finding also 
bring to light new questions remain to be answered.  Hopefully, continued research on this topic 
will advance our understanding of the basic biology tau, clarify the possible contributions of the 
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tau 3’-UTR and/or miR-34a to AD, and allow the development of novel therapeutic strategies for 
treating AD and possibly other tauopathies. 
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Appendix  
Characterization of Differentiated SH-SY5Y Cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental contributions to the appendix:  John Dickson performed all of the experiments 
presented in the appendix. 
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Introduction 
 In theory, the best cell culture model system to study a human gene involved in the 
function of neurons would be a primary culture of human neurons.  However, in practice, there 
are a number of challenges that make the system less than ideal.  New samples of human brain 
tissue containing viable neurons are required to initiate each new culture.  Because of the 
inherent genetic variability in the human population, each culture will have its own unique 
genetic background, which can be a confounder in experiments.  Additionally, the ability to 
perform experiments in primary human neurons is limited by the availability of suitable brain 
tissue from which to obtain cultures.   
One alternative to using primary human neurons is to use human cancerous or 
transformed cells of neuronal origin, which can be maintained in culture.  This allows for a ready 
supply of cells in the lab for experiments and provides consistency among experiments, as the 
same cell line can be used for all of the experiments.  A disadvantage of this system is that the 
cancerous or transformed cells are genetically abnormal and are not fully differentiated neurons.  
Another possible alternative, which could in some ways be considered to be a compromise 
between human primary neurons and cultured cancerous or transformed human cells, is to use 
primary neurons from rat or mouse brains.  These neurons can be readily obtained from rodents 
kept for research purposes, and the use of inbred laboratory strains allows the rodent primary 
neurons to have a more homogenous genetic background than is possible with human primary 
neurons.  A disadvantage of using rodent primary neurons to study human genes is that these 
neurons are not derived from humans.  In many cases, this is not a major problem due to 
conservation of genes between rodents and humans. 
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In the case of studying the human tau 3’-UTR, rodent primary neurons are not an ideal 
model system because the rodent and human tau 3’-UTRs are not well conserved (Poorkaj et al., 
2001).  Additionally, human primary neurons are not ideal for these studies for the reasons 
discussed above.  Therefore, cultured human cells were chosen as model system for studying the 
human tau 3’-UTR.  One of the cell lines chosen for these studies was the SH-SY5Y human 
neuroblastoma cell line, which grows neurites when differentiated by sequential treatment with 
retinoic acid and BDNF (Encinas et al., 2000).  Having axon-like neurites is particularly 
important for cells used to study the possible function of the human tau 3’-UTR in directing the 
subcellular localization of tau mRNA.  In order to determine the suitability of differentiated SH-
SY5Y cells for studies involving the function of the human tau 3’-UTR, the cells were 
characterized in with regard to their expression of the tau 3’-UTR, their ability to form axon-like 
and dendrite-like neurites, and their pattern of tau mRNA localization. 
Methods 
Cell Culture 
 The culture and differentiation of SH-SY5Y cells were performed as described in Chapter 
2.  For cells to be imaged by microscopy, cells were cultured on fibronectin-coated coverslips 
placed in the wells of a 24-well plate.  For the coating of sterile glass coverslips with fibronectin, 
2 µg fibronectin from human plasma (Sigma-Aldrich) were diluted in 100 µL Dulbecco’s 
phosphate-buffered saline (DPBS) (Life Technologies) per well.  The coverslip was placed in a 
well, and the diluted fibronectin solution was added to the well and allowed to incubate at room 
temperature for 45 minutes.  
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Preparation of Human Frontal Cortex cDNA 
 Human frontal cortex total RNA (Agilent Technologies) was reverse transcribed to 
cDNA using Double Primed RNA to cDNA EcoDry Premix (Clontech) according to the 
manufacturer’s instructions. 
Polymerase Chain Reaction (PCR) 
 Sequences spanning human tau exon 13 to 3’-UTR (TauEx13-3UTR), human long tau 3’-
UTR only (Tau_long3UTR), and GAPDH were amplified from human frontal cortex cDNA by 
PCR using KAPA HiFi HotStart ReadyMix (Kapa Biosystems) according to the manufacturer’s 
instructions, with an annealing temperature of 65ºC.  The primers used for PCR are listed in 
Table A.1. 
Table A.1.   Primers Used in the Cloning of Tau and GAPDH Probes. 
Construct Location Orientation Sequence (5’ to 3’) 
TauEx13-3UTR Ex13 65-88 Forward CTAGCCTCGAGAATTCTCGTGTACAAGTCGCCAG
TGGTGT 
TauEx13-3UTR 3UTR 112-
138 
Reverse GGGAAGCGGCCGCCCGGGGCCGGGTCATTATTC
CCAATTAACCGA 
Tau_long3UTR 3UTR 
2847-2866 
Forward CTAGCCTCGAGAATTCCCCTGCCGTTCGCTGAGT
CC 
Tau_long3UTR 3UTR 
3115-3136 
Reverse GGGAAGCGGCCGCCCGGGATCTGCCAGCACTGA
TCACCCT 
GAPDH Ex8 95-116 Forward CTAGCCTCGAGAATTCCCTGCCTCTACTGGCGCT
GC 
GAPDH Ex8 368-
387 
Reverse GGGAAGCGGCCGCCCGGGGTTGAGGGCAATGCC
AGCCC 
 
Restriction Digest of pCI-neo Vectors 
 The pCI-neo Mammalian Expression Vector (Promega) contains a T7 RNA polymerase 
promoter 5’ to the multiple cloning site and a T3 RNA polymerase promoter 3’ to the multiple 
cloning site.  Additionally, it contains an ampicillin resistance gene to allow for selection in 
bacteria.  The pCI-neo vector and constructs based on the pCI-neo vector were subjected to 
restriction digests in 1X Buffer 4 (New England Biolabs), 1X bovine serum albumin (New 
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England Biolabs), and 0.5 µL the desired restriction enzyme (New England Biolabs) in a total 
reaction volume of 50 µL.  SmaI digests were performed at 25 ºC for 30 min.  EcoRI digests 
were performed at 37 ºC for 30 min.  Double digests were performed sequentially, with the SmaI 
digest followed by the EcoRI digest.  Restriction enzymes were inactivated by incubation at 65 
ºC for 20 min.  NotI-HF digests were performed at 37 ºC for 1 h. 
Agarose Gel Electrophoresis 
 Agarose gel electrophoresis was performed as described in Chapter 2. 
Gel Extraction of DNA 
 Gel extraction of DNA was performed as described in Chapter 2. 
Cloning 
 Cloning was performed as described in Chapter 2. 
Transformation of Bacteria 
 Transformation of bacteria was performed as described in Chapter 2. 
Plasmid Preparation 
 Plasmid preparation was performed as described in Chapter 2. 
Preparation of Biotinylated dsDNA Northern Blot Probes by PCR 
 The TauEx13-3UTR, Tau_long3UTR, and GAPDH constructs were used as templates for 
PCR doped with biotinylated dUTP using the SuperTaq Plus Polymerase (Life Technologies) 
using the primers in Table A1.1 with the following reaction conditions: 
100 ng DNA template 
5.0 µl 10X Long PCR Buffer (Life Technologies) 
1.0 µL 10 mM dATP (Life Technologies) 
1.0 µL 10 mM dCTP (Life Technologies) 
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1.0 µL 10 mM dGTP (Life Technologies) 
0.6 µL 10 mM dTTP (Life Technologies) 
4.0 µL 1 mM biotin-16-dUTP (Roche) 
0.25 µL 5 U/µL SuperTaq Plus Polymerase (Life Technologies) 
2 µL 10 µM Forward Primer 
2 µL 10 µM Reverse Primer 
The PCR cycles were performed according to protocol provided with SuperTaq Plus 
Polymerase with an annealing temperature of 62 ºC.  The biotinylated dsDNA probes generated 
by PCR were subjected to agarose gel electrophoresis and gel extraction as described above. 
Preparation of Nonisotopically Labeled ssRNA Fluorescence in situ Hybridization Probes by in 
vitro Transcription 
 The TauEx13-3UTR, Tau_long3UTR, and GAPDH constructs were digested with EcoRI 
as described above for preparation as a template for in vitro transcription of antisense ssRNA 
probes or with NotI-HF as described above for preparation as a template for in vitro transcription 
of sense ssRNA probes.  The in vitro transcription was performed with the MAXIscript Kit (Life 
Technologies) according to the manufacturer’s instructions for nonisotopic labeling with 
digoxigenin-11-UTP (Roche).  The T3 RNA polymerase was used for the in vitro transcription 
of antisense probes, while the T7 RNA polymerase was used for the in vitro transcription of 
sense probes.  Both of these RNA polymerases are included in the MAXIscript Kit.  The labeled 
ssRNA products of in vitro transcription were precipitated with ammonium acetate according to 
the MAXIscript Kit protocol, and they were resuspended in nuclease-free water (Life 
Technologies). 
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PAGE Purification of ssRNA Probes 
 The biotinylated ssRNA products of in vitro transcription were purified by PAGE 
according to the MAXIscript Kit protocol.  The bands were visualized by UV shadowing using a 
Fluor-Coated TLC Plate (Life Technologies) under short wave UV illumination.  The bands were 
excised from the gel, fragmented, and placed in a probe elution buffer consisting of 0.5 M 
ammonium acetate, 1 mM EDTA, and 0.2% SDS, and incubated at 37 ºC overnight.  The eluted 
probe was precipitated by the ammonium acetate precipitation protocol provided with the 
MAXIscript Kit. 
Total RNA Isolation 
 Total RNA isolation was performed as described in Chapter 2. 
Northern Blot 
 Agarose gel electrophoresis of 6 µg total RNA was performed with the NorthernMax-Gly 
Kit (Life Technologies) according to the manufacturer’s protocol.  The RNA was transferred to a 
the BrightStar-Plus Positively Charged Nylon Membrane (Life Technologies) by electroblotting 
using the Genie Blotter (Idea Scientific) in 1X NorthernMAX MOPS Gel Running Buffer (Life 
Technologies) at 12 V for 1 h according to the protocol provided with the Genie Blotter.  
Following the transfer, the RNA was crosslinked to the membrane by baking at 80 ºC for 15 min.  
During the crosslinking, ULTRAhyb hybridization buffer (Life Technologies) was preheated to 
42 ºC.  The crosslinked membrane was placed in a hybridization tube, to which 10 mL preheated 
ULTRAhyb buffer was added.  The membrane was prehybridized in the ULTRAhyb buffer for 
at least 30 min at 42 ºC with rotation in a roller oven.  During the prehybridization, the 
biotinylated dsDNA probe was prepared for hybridization:  37.5 ng of biotinylated dsDNA probe 
was heat denatured in 50 µL 10 mM EDTA at 90 ºC for 10 min.  At the end of the probe 
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denaturation, 0.5 mL ULTRAhyb buffer used in the prehybridization was removed from the 
hybridization tube, and the denatured probe was added to it.  The ULTRAhyb buffer containing 
the probe was added back to the hybridization tube containing the membrane and the rest of the 
ULTRAhyb buffer from the prehybridization.  The hybridization tube was placed in the roller 
oven, and the probe was hybridized to the membrane at 42 ºC overnight with rotation.  Following 
the hybridization, the membrane was subjected to a low stringency wash in a 2X SSC, 0.1% SDS 
solution for 10 min and room temperature.  The membrane was then subjected to two high 
stringency washes in a 0.1X SSC, 0.1% SDS solution for 15 min each at 42 ºC.  The biotinylated 
probes were visualized using the BrightStar BioDetect Nonisotopic Detection Kit (Life 
Technologies) according to the manufacturer’s instructions with wash times following incubation 
with the Strep-Alkaline Phosphatase extended to 15 minutes each.  The substrate for alkaline 
phosphatase included with the kit is CDP-Star.  The probes were stripped from the membrane by 
pouring 200 mL boiling 0.1% SDS solution over it and allowing the SDS solution to cool to 
room temperature.  The stripping was repeated with another 200 mL of boiling 0.1% SDS 
solution. 
Immunofluorescence (IF) 
 Cells were washed with phosphate buffered saline (PBS) and fixed in 3.65% 
formaldehyde (Sigma-Aldrich) in PBS for 15 min at room temperature.  The cells were then 
rinsed twice with ice-cold PBS.  Cells were permeablized in 0.25% Triton X-100 in PBS for 10 
min at room temperature.  Cells were washed three times in PBS for 5 min each.  Blocking was 
performed by incubating cells in 1% bovine serum albumin in PBS containing 0.1% Tween-20 
(PBST) containing 0.3M glycine.  Mouse anti-tau antibody (AnaSpec) and/or rabbit polyclonal 
anti-MAP2 antibody (Abcam) were diluted 1:100 in 1% bovine serum albumin in PBST and 
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incubated with the cells in a humidified chamber for 1 h.  Cells were washed three times in PBS 
for 5 min each.  Secondary antibodies were diluted 1:100 in 1% bovine serum albumin in PBST 
and incubated with the cells in a humidified chamber in the dark for 1 h.  For single IF, 
secondary antibodies Alexa Fluor 488 Goat Anti-Mouse and Alexa Fluor 488 Goat Anti-Rabbit 
(Life Technologies) were used.  For double IF, Alexa Fluor 594 Goat Anti-Mouse and Alexa 
Fluor 488 Goat Anti-Rabbit (Life Technologies) were used.  Cells were washed in the dark three 
times in PBS for 5 min each.  The nuclear counterstain TO-PRO-3 (Life Technologies) was 
diluted 1:2,000 in PBS and incubated with the cells for 5 min in the dark.  Cells were washed 
once in PBS for 5 min and then dipped in purified water.  A drop of VECTASHIELD Mounting 
Medium with DAPI (Vector Laboratories) was placed on a glass microscope slide, and the 
coverslip was placed cell side down on the drop.  Any air bubbles were pressed out with gentle 
pressure on the coverslip.  The edges were sealed using clear SALON Nail Lacquer (Sally 
Hansen), which was allowed to air dry.  The cells were imaged using a Zeiss LSM 510 confocal 
microscope. 
Fluorescence in situ Hybridization (FISH) 
 Hybridization solution was prepared according to the following recipe, aliquoted, and 
stored at -20 ºC until needed.  Hybridization solution recipe: 
10 mM Tris HCl, pH 7.5 (Life Technologies) 
600 mM NaCl (Life Technologies) 
1 mM EDTA (Life Technologies) 
0.25% SDS (Life Technologies) 
10% (w/v) dextran sulfate (Sigma-Aldrich) 
1X Denhardt’s solution (Sigma-Aldrich) 
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200 µg/mL yeast tRNA (Life Technologies) 
50% formamide (Life Technologies) 
Cells were washed with phosphate buffered saline (PBS) and fixed in 3.65% 
formaldehyde (Sigma-Aldrich) in PBS for 10 min at room temperature.  Cells were washed three 
times in PBS for 3 min each.  Endogenous peroxidase activity was blocked by treat with 0.2 N 
HCl (Sigma-Aldrich) for 20 min at room temperature.  Cells were washed twice in PBS for 3 
min each.  Acetylation to prevent endogenous RNase activity was performed by incubating cells 
in 0.1 M triethanolamine (Sigma-Aldrich) containing 2.5 µL/mL acetic anhydride (Sigma-
Aldrich).  Cells were permeablized by incubating with 0.1% Triton X-100 in PBS for 30 min.  
Cells were washed three times in PBS for 5 min each.  Cells were incubated in 500 µL 
hybridization solution for 1 h.  The hybridization oven was preheated to 65 ºC for during this 
incubation.  The digoxigenin-labeled ssRNA probes were prepared for hybridization by adding 
10 ng of the probe to 30 µL of the hybridization solution and heating to 80 ºC for 5 min.  The 
probe was then immediately placed on ice following denaturation.  The denatured probe was 
place on the upside down lid of the 24-well plate the cells were cultured in.  The coverslip was 
placed cell side down on the drop of the denatured probe.  The probe and cells were incubated 
overnight in the hybridization oven at 65 ºC in a humidified container containing 50% 
formamide (Life Technologies) in 5X SSC (Life Technologies).  The coverslips were briefly 
rinsed in 5X SSC.  The coverslips were then washed twice in 0.2X SSC at 65 ºC for 20 min each.  
The coverslips were washed in a buffer consisting of 0.1 M Tris HCl, pH 7.5, 0.15 M NaCl, and 
0.05% Tween-20 (referred to as TNT wash buffer) for 5 min.  The coverslips were blocked in 0.1 
M Tris HCl, pH 7.5, 0.15 M NaCl, and 0.5% Blocking Reagent (PerkinElmer) (referred to as 
TNB buffer) in a humidified chamber at room temperature for 30 min.  Anti-digoxigenin 
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antibody conjugated to HRP (Abcam) was diluted 1:500 in TNB buffer and incubated with the 
coverslip at 4 ºC overnight.  The coverslips were washed three times in TNT wash buffer at room 
temperature for 5 min.  Tyramide Signal Amplification (TSA) was performed using the TSA 
PLUS Fluorescence Kit (PerkinElmer).  The fluorescein dye was reconstituted in 150 µL DMSO.  
The stock dye was diluted 1:50 in 1X Plus Amplification Diluent provided with the kit.  The 
diluted dye (300 µL/coverslip) was added to the coverslip and incubated in the dark at room 
temperature for 10 min.  The coverslips were washed three times in TNT wash buffer in the dark 
at room temperature for 5 min.  The nuclear counterstain TO-PRO-3 was diluted 1:2,000 in PBS 
and incubated with the cells for 5 minutes in the dark.  Cells were washed once in PBS for 5 min 
and then dipped in purified water.  A drop of VECTASHIELD Mounting Medium with DAPI 
was placed on a glass microscope slide, and the coverslip was placed cell side down on the drop.  
Any air bubbles were pressed out with gentle pressure on the coverslip.  The edges were sealed 
using clear SALON Nail Lacquer, which was allowed to air dry.  The cells were imaged using a 
Zeiss LSM 510 confocal microscope. 
Results 
 In order to determine if differentiated SH-SY5Y cells express both isoforms of the human 
tau 3’-UTR, total RNA from differentiated SH-SY5Y cells was subjected to Northern blot, and 
the tau mRNA bands were visualized using a probe for total tau.  GAPDH was probed as a 
loading control.  Total RNA from human frontal cortex was included in the Northern blot 
analysis for comparison.  The postmortem frontal cortex RNA sample is somewhat degraded, but 
the full-length 6 kb transcript, which corresponds to the long tau 3’-UTR isoform is prominent.  
The two transcripts corresponding to the tau 3’-UTR isoforms are visible at approximately 6 kb 
and 2 kb in the differentiated SH-SY5Y cells (Figure A.1).  Thus, differentiated SH-SY5Y cells  
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Figure A.1.  Northern Blot of Tau mRNA in Differentiated SH-SY5Y Cells.  Total 
RNA from human frontal cortex (FC) and differentiated SH-SY5Y (SH) was analyzed by 
Northern blot.  A probe for total tau (TauEx13-3UTR) was used.  GAPDH included as a 
loading control. 
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are a good model system for studying the human tau 3’-UTR in that they express both isoforms 
endogenously. 
 The neurites of differentiated SH-SY5Y cells were characterized by immunofluorescence 
(IF), with staining for tau, which is an axonal marker, and the dendritic marker MAP2 (Goedert 
et al., 1991).  In single IF experiments, tau and MAP2 stained the neurites, as well as the soma 
(Figure A.2).  In order to determine if tau and MAP2 stain distinct neurites, double IF was 
performed, with simultaneous staining for tau and MAP2.  Two distinct types of neurites were 
seen:  one that is predominantly stained by tau and another that is predominantly stained by 
MAP2 (Figure A.3).  This indicates that differentiated SH-SY5Y cells have distinct axon-like 
tau-positive neurites and dendrite-like MAP2-positive neurites.   
 The subcellular localization of tau mRNA in differentiated SH-SY5Y cells was 
visualized using fluorescence in situ hybridization (FISH).  Total tau mRNA was visualized with 
biotinylated antisense probe (TauEx13-3UTR_A).  This revealed staining of tau mRNA in the 
soma and neurites (Figure A.4A).  As a control, the sense probe was used, and it revealed less 
intense staining, primarily in the soma (Figure A.4B), which may represent non-specific signal.  
No background autofluorescence was detected (Figure A.4C). 
Discussion 
These findings presented here suggest differentiated SH-SY5Y cells may be a good 
model for studying the functions of the human tau 3’-UTR.  Given the presence of distinct axon-
like tau-positive neurites and dendrite-like MAP2-positive neurites in differentiated SH-SY5Y 
cells, they are a particularly attractive model for studying the subcellular localization of tau 
mRNA.  However, further optimization of the hybridization conditions in the FISH experiment 
should be attempted to eliminate any non-specific signal.  Additionally, combined FISH for tau  
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1º:  mouse anti-tau 
2º:  goat anti-mouse 
1º:  rabbit anti-MAP2 
2º:  goat anti-rabbit 
+ 1º Antibody - 1º Antibody 
A B 
C D 
Figure A.2.   Tau and MAP2 Proteins are Present in the Neurites of Differentiated SH-
SY5Y Cells.  Tau (A) and MAP2 (C) proteins (green) were visualized in differentiated SH-
SY5Y cells by immunofluorescence.  No signal was seen with AlexaFluor 488-conjugated 
secondary antibodies only (primary antibody omitted) (B and D).  Nuclei were counterstained 
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Figure A.3. Tau and MAP2 Proteins Label Distinct Neurites in Differentiated SH-
SY5Y Cells. Differentiated SH-SY5Y cells were fixed and double immunofluorescence was 
performed using anti-tau and anti-MAP2 primary antibodies (A).  Minimal staining by 
secondary antibodies alone was seen in a control in which primary antibodies were omitted.  
Cells were visualized by confocal microscopy. 
	  	  104 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C 
Figure A.4.  Localization of Tau mRNA in Differentiated SH-SY5Y Cells. Fluorescent in 
situ hybridization (FISH) was performed on differentiated SH-SY5Y cells using tyramide 
signal amplification with fluorescein dye (green).  Nuclei were counterstained with TO-PRO-
3 (blue).  (A) Antisense TauEx13-3UTR_A probe.  (B) Sense TauEx13-3UTR_S probe.  (C) 
no probe, no anti-DIG-HRP. 
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mRNA and double IF for tau and MAP2 proteins should be performed to determine the extent to 
which tau mRNA localizes in tau-positive axon-like neurites.   
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